



(86) Date de dépôt PCT/PCT Filing Date: 2005/12/12
(87) Date publication PCT/PCT Publication Date: 2006/06/22
(45) Date de délivrance/Issue Date: 2013/10/22
(85) Entrée phase nationale/National Entry: 2007/06/13
(86) N° demande PCT/PCT Application No.: US 2005/045097
(87) N° publication PCT/PCT Publication No.: 2006/065827
(30) Priorités/Priorities: 2004/12/13 (US60/635,561);
2005/04/25 (US60/674,488)

(51) Cl.Int./Int.Cl. *C12N 5/00* (2006.01),
C12N 5/16 (2006.01)
(72) Inventeurs/Inventors:
HOWE, JOHN A., US;
SHERRILL, SCOTT J., US;
WILLS, KEN, US;
RALSTON, ROBERT ORVILLE II, US
(73) Propriétaire/Owner:
CANJI, INC., US
(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : LIGNEES CELLULAIRES POUR LA PRODUCTION D'ADENOVIRUS DEFECTIFS POUR LA REPLICATION
(54) Title: CELL LINES FOR PRODUCTION OF REPLICATION-DEFECTIVE ADENOVIRUS

(57) **Abrégé/Abstract:**

The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus ("RCA").



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/065827 A3

(51) International Patent Classification:

C12N 5/00 (2006.01) C12N 5/16 (2006.01)

(21) International Application Number:

PCT/US2005/045097

(22) International Filing Date:

12 December 2005 (12.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/635,561 13 December 2004 (13.12.2004) US
60/674,488 25 April 2005 (25.04.2005) US

(71) Applicant (for all designated States except US): **CANJL, INC.** [US/US]; 901 California Avenue, Palo Alto, California 92121 (US).

(71) Applicants and

(72) Inventors: **HOWE, John, A.** [US/US]; 71 Ridge Road, Greenbrook, New Jersey 08812 (US). **SHERRILL, Scott, J.** [US/US]; 611 Packford Drive, Chesterfield, Missouri 63017 (US). **WILLS, Ken** [US/US]; 7806 Via Opuntia, Carlsbad, California 92009 (US). **RALSTON, II, Robert, Orville** [US/US]; 859 Dewey Street, Union, New Jersey 07083 (US).

(74) Agent: **GRUPPI, Carol, M.**; Schering-Plough Corporation, Patent Department, K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
12 October 2006

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 34/2006 of 24 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CELL LINES FOR PRODUCTION OF REPLICATION-DEFECTIVE ADENOVIRUS

(57) Abstract: The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus ("RCA").

WO 2006/065827 A3

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

Cell Lines for Production of Replication-Defective Adenovirus

5

10

1. FIELD OF THE INVENTION

The present invention relates to cell lines useful for the efficient production of replication-defective adenoviruses. The invention also describes methods of use of such cell lines to produce replication-defective adenoviruses.

2. BACKGROUND OF THE INVENTION

15

20

25

Recombinant adenovirus (rAd) vectors have desirable features for gene delivery, including wide tissue and cell tropism, the capacity to accommodate large expression cassettes and high transduction efficiency. In addition, adenovirus is well suited for pharmaceutical development as the virus grows to high specific titers and scalable manufacturing processes have been established (Huyghe *et al.*, (1995) Hum. Gene Ther. 6:1403-1416; Shabram *et al.*, (1997) Hum. Gene Ther. 8:453-465). Production of rAd vectors requires engineered cell lines that can complement functions removed from the viral genome. For pharmaceutical development and commercial manufacture of viral vectors, the vector-cell line combination also must be amenable to scale-up and provide material of sufficient quality and purity.

30

Replication defective rAd vectors for gene therapy use are generally deleted for the viral early region 1 (E1). E1 contains two transcription units, E1A and E1B, which encode a number of proteins that have critical roles in the early and late phases of the lytic cycle. Production of rAd vectors requires complementation of these E1 activities. E1A and E1B gene functions have been extensively

characterized. A review of E1A and E1B functions is provided in Bayley, *et al.* (1994) International J. of Oncology 5:425-444 and Shenk, *et al.* (1996) in Adenoviridae: The Viruses and Their Replication, Fields Virology (K.D.M. Fields B.N., and Howley, P.M., Ed.), 2 Lippincott-Raven, Philadelphia, PA. The first E1-complementing line, 293, was generated by transfection of primary embryonic kidney cells using physically sheared adenovirus 5 DNA (Graham *et al.*, (1977) J Gen. Virol. 36:59-74). Genomic analysis subsequently demonstrated that 293 cells carry an integrated fragment of the left-hand end of adenovirus genome (bases 1 - 4344), containing the E1 region and additional flanking sequences (Louis *et al.*, (1997) Virology 233:423-429).

Although 293 cells produce E1-deficient rAd vectors at acceptable levels, an undesirable contaminant called replication competent adenovirus ("RCA") is sometimes generated by homologous recombination between the rAd vector and the adenovirus sequences present in the 293 genome (Lochmuller *et al.*, (1994) Hum. Gene Ther. 5:1485-1491; Zhu *et al.*, (1999) Hum. Gene Ther. 10:113-121). To reduce the risk of generation of RCA by homologous recombination, Fallaux *et al.*, (Hum. Gene Ther. 9:1909-1917 (1998)) transfected human embryonic retinoblasts with a recombinant plasmid containing E1 genes, in which the E1A promoter and E1B polyadenylation sequences were replaced by heterologous control elements. Deletion of the adenovirus flanking sequences in the E1 plasmid yielded a cell line, PER.C6, which does not generate RCA through homologous recombination when cell line-matched rAd vectors are employed (Fallaux *et al.*, (1998) Hum. Gene Ther. 9:1909-1917). However, recent studies have shown that an atypical form of RCA, called helper-dependent E1-positive particles, can be formed when non-matched adenoviral vectors are propagated in PER.C6 cells (Murakami *et al.*, (2002) Hum. Gene Ther. 13:1909-1920).

The E1 region used for complementation of E1-deleted adenoviruses in 293 cells and PER.C6 cells includes the entire E1B transcription unit, which encodes two major proteins: E1B-19K and E1B-55K. In adenovirus replication, the E1B-19K and E1B-55K proteins function in the early lytic cycle to limit E1A-induced apoptosis (Querido *et al.*, (1997) J. Virol. 71:3788-3798; Rao *et al.*, (1992) Proc. Natl. Acad.

Sci. USA 89:7742-7746; White *et al.*, (1991) J. Virol. 65:2968-2978). In addition, E1B-55K functions in the late phase to stimulate the accumulation and translational of viral late mRNAs (Babiss *et al.*, (1985) Mol. Cell Biol. 5:2552-2558; Harada and Berk, (1999) J. Virol. 73:5333-5344). E1B has also has been shown to collaborate with E1A in transforming primary cells (Branton *et al.*, (1985) Biochim. Biophys. Acta 780:67-94), and specifically protects against E1A sensitization to apoptosis (White *et al.*, (1991) J. Virol. 65:2968-2978).

The construction of stable human cell lines that effectively and efficiently complement replication deficient adenoviral vectors can be difficult. A barrier for developing E1-complementing cell lines is the toxicity associated with high levels of E1A gene product expression. For example, constitutive expression of the E1 proteins, especially E1A, has proven difficult in established cell lines (Imler *et al.*, (1996) Gene Ther. 3:75-84). E1A has been shown to suppress cell growth and induce anoikis (Frisch, (1991) Proc Natl Acad Sci USA 88:9077-9081; Frisch and Mymryk, (2002) Nat Rev Mol Cell Biol 3:441-452; Mymryk *et al.*, (1994) Oncogene 9: 1187-1193; Rao *et al.*, (1992) Proc Natl Acad Sci USA 89:7742-7746). Thus, complementation cell lines, such as those known in the art, that constitutively express E1A proteins may be associated with poor survival rates prior to and/or during adenoviral vector production.

Others have previously used human tumor cell lines, such as the A549 cell line, to develop E1-complementing cell lines. For example, Massie (U.S. Patent 5,891,690) transformed A549 cells with an E1 region expression cassette in which the adenovirus E1A promoter was replaced with the human alpha-actin promoter. However, the yield of an adenovirus gene therapy vector expressing the bacterial beta-galactosidase gene was shown to be lower than from 293 cells. Imler, *et al.* used regulated induction of E1 as a strategy to avoid toxicity associated with constitutive expression of E1A, allowing generation of rAd producer cell lines based on A549 cells (Imler, *et al.*, (1996) Gene Ther. 3:75-84). Production yields of rAd vectors from these Gal4-inducible producer cell lines were reported to be 5-10 fold lower than from 293 cells (Imler, *et al.*, *supra*).

Accordingly, there is a need for more efficient recombinant cell lines to produce replication-defective adenoviruses (*i.e.*, adenoviruses containing a deletion of the E1A and E1B coding regions of the adenoviral genome) which have low RCA and with production levels on the order of wild-type adenovirus production from the 293 cell line.

3. SUMMARY OF THE INVENTION

The present invention addresses the foregoing needs by providing new cell lines for the production of recombinant adenovirus based on combining selected viral and host functions required for adenovirus replication.

The present invention provides helper adenovirus nucleic acid sequences for use in the generation of host cells that complement the recombinant adenovirus vectors and recombinant adenoviruses described herein. The helper adenovirus nucleic acid sequences of the present invention: (i) provide viral functions for the replication of a recombinant adenovirus vector and/or its packaging into infectious virions; and (ii) are not replicated or assembled into viral particles to a measurable degree. The helper adenovirus nucleic acid sequences can be obtained and/or derived from any adenoviridae or a combination of adenoviridae. In a preferred embodiment, the helper adenovirus nucleic acid sequences are obtained and/or derived from a human adenoviridae.

In one embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E1B protein(s), such as E1B-55K and/or E1B-19K. In accordance with this embodiment, the helper adenovirus nucleic acid sequences may also include one, two or more of the following: (i) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E2 protein(s); (ii) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E4 protein(s); and/or (iii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral L4 100K protein. Non-

limiting examples of adenoviral E2 proteins include E2A binding protein, E2B polymerase, E2B pre-terminal protein, and E2B IVa2 protein. Non-limiting examples of adenoviral E4 proteins include those encoded by open reading frame (ORF)-6, ORF3, and ORF6/7. Table 1 below provides examples of the nucleotide and amino acid sequences of human adenovirus serotype 5 E1A proteins, E1B-55K protein, E1B-19K protein and E2B polymerase protein.

Table 1: Sequences of the invention.

Sequence	Sequence Identifier
plasmid pRcRSV-E1Adl01/07	SEQ ID NO: 1
plasmid pcDNA3.1(+)-E1B 55K Hygro	SEQ ID NO: 2
nucleotide sequence encoding human adenovirus type 5, 289R E1A, wild type	SEQ ID NO: 3
amino acid sequence of human adenovirus type 5, 289R E1A, wild type, protein	SEQ ID NO: 4
nucleotide sequence of human adenovirus type 5, 243R E1A, wild type	SEQ ID NO: 5
amino acid sequence of human adenovirus type 5, 243R E1A, wild type, protein	SEQ ID NO: 6
amino acid residues 4-25 of human adenovirus type 5, E1A 289R, wild type, protein	SEQ ID NO: 7
amino acid residues 4-25 of human adenovirus type 5, E1A 243R, wild type, protein	SEQ ID NO: 8
amino acid residues 36-49 of human adenovirus type 5, E1A 289R, wild type, protein	SEQ ID NO: 9
amino acid residues 36-49 of human adenovirus type 5, E1A 243R, wild type, protein	SEQ ID NO: 10
amino acid residues 111-123 of human adenovirus type 5, E1A 289R, wild type, protein	SEQ ID NO: 11
amino acid residues 111-123 of human adenovirus type 5, E1A 243R, wild type, protein	SEQ ID NO: 12
amino acid residues 124-127 of human adenovirus type 5, E1A 289R, wild type, protein	SEQ ID NO: 13
amino acid residues 124-127 of human adenovirus type 5 E1A 243R, wild type, protein	SEQ ID NO: 14
nucleotide sequence of human adenovirus type 5, E1B-55K, coding region	SEQ ID NO: 15
amino acid sequence of human adenovirus type 5, E1B-55K, protein	SEQ ID NO: 16
nucleotide sequence of human adenovirus type 5, E1A gene	SEQ ID NO: 17
nucleotide sequence of human adenovirus type 5, E1B-55K and E1-19K, coding regions	SEQ ID NO: 18
plasmid pVITRO21RESPuroE1b	SEQ ID NO: 19
plasmid pMGCME2Bbpol	SEQ ID NO: 20
nucleotide sequence of human adenovirus type 5, E1B-19K, coding	SEQ ID NO: 21

region	
amino acid sequence of human adenovirus type 5, E1B-19K, protein	SEQ ID NO: 22
nucleotide sequence of human adenovirus type 5, E2B, coding region	SEQ ID NO: 25
nucleotide sequence of human adenovirus type 5, E2B polymerase, coding region	SEQ ID NO: 23
amino acid sequence of human adenovirus type 5, E2B polymerase, protein	SEQ ID NO: 24
nucleotide sequence of E1Adl01/07	SEQ ID NO:26
Amino acid sequence of E1Adl01/07	SEQ ID NO:27

In a specific embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B protein, wherein the E1B protein comprises an E1B-55K protein but not an E1B-19K protein. In a preferred embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (iii) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins.

To produce E1A proteins that are defective for binding to the cellular proteins p300/CBP and pRb, mutations in the E1A 289R and E1A 243R coding regions can be introduced. In a specific embodiment, the E1A proteins comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. In a preferred embodiment, the E1A proteins comprise: (a) a

first deletion corresponding to amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); and (b) a second deletion corresponding to amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein.

5 The present invention provides host cells transfected or transformed with the helper adenovirus nucleic acid sequences. Such cells are useful in the production of recombinant adenovirus, in particular replication-defective recombinant adenovirus. The host cells of the present invention complement functions missing from the recombinant adenovirus vector or recombinant
10 adenovirus of interest (*i.e.*, the adenoviral E1A, for example, SEQ ID NO: 17, and E1B, for example, SEQ ID NO: 18, coding regions). Preferably, the host cells contain complementing adenoviral genes that lack any homology to those in the recombinant adenoviral vector of interest, which reduces the possibility of the viral genome recombining with the cellular DNA to produce replication competent
15 adenovirus. Host cells that complement the recombinant adenovirus vectors and recombinant adenoviruses described herein are sometimes referred to herein as "complementing cell lines", "rAd production cell lines", "rAd complementation cells" and "rAd complementation cell lines".

 In a specific embodiment, the present invention provides an isolated host
20 cell comprising: (a) first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein. In accordance with this embodiment, the second nucleic acid molecule, in certain
25 embodiments, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein. Further, in accordance with this embodiment, the host cell may further comprise additional nucleic acid molecules comprising nucleotide sequences encoding an adenoviral E2a DNA binding protein, an adenoviral E2b pre-terminal protein, an adenoviral E2b IVa2 protein, adenoviral E4 proteins (*e.g.*, ORF 6, ORF 3
30 and ORF 6/7 of an adenoviral E4 gene), and/or an adenoviral protein encoded by L4 100K.

In a preferred embodiment, the present invention provides an isolated host cell comprising: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins. In accordance with this embodiment, the host cell may further comprise additional nucleic acid molecules comprising nucleotide sequences encoding an adenoviral E2a DNA binding protein, an adenoviral E2b pre-terminal protein, an adenoviral E2b IVa2 protein, adenoviral E4 proteins (*e.g.*, ORF 6, ORF 3 and ORF 6/7 of an adenoviral E4 gene), and/or an adenoviral protein encoded by L4 100K.

In a specific embodiment, the E1A proteins expressed by the host cells comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d*/1108) of an E1A 289R protein and amino acid residues 124-127 (*d*/1108) of an E1A 243R protein. In a preferred embodiment, the E1A proteins expressed by the host cells comprise: (a) a first deletion corresponding to amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); and (b) a second deletion corresponding to amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein.

Any type of cell may be used as a host cell. In a preferred embodiment, a cell that is permissible to adenovirus, preferably human adenovirus, infection is used. In a preferred embodiment, human cells (including primary cells and cell lines) are used as host cells. Human established cell lines such as those from human tumor cells or human tumor cell lines have the ability to replicate

indefinitely in culture. In a specific embodiment, the host cell is a A549, HCT-15, IGROV-1, HeLa, U87, W162 or 293-D22 cell. In a preferred embodiment, the host cell is a A549 cell.

In one embodiment, the present invention provides a human cell comprising

5 stably integrated nucleic acid sequences comprising: (a) a first expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said proteins are expressed in said human cell; and (b) a second expression cassette comprising a

10 promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E1B protein, wherein said E1B protein comprises an E1B-55K protein but not an E1B-19K protein, wherein said E1B-55K protein is expressed in said human cell. In a particular embodiment, the E1A proteins expressed by the human cell comprise: (a) a first deletion corresponding to: (i) amino acid residues

15 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino

20 acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. In a preferred embodiment the E1A proteins expressed by the human cell comprise: (a) a first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein (*d/1101*); and (b) a second deletion

25 corresponding to amino acid residues 111-123 (*d/1107*) of said E1A 289R protein and amino acid residues 111-123 (*d/1107*) of said E1A 243R protein.

The present invention provides the above human cells, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26 and/or the second expression cassette comprises the nucleic acid sequence set

30 forth in SEQ ID NO: 15. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1 and/or the second

expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 2. The present invention also provides the above human cell, wherein the cell is designated SL0003, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6231. In a specific embodiment of the invention, the recombinant adenovirus production cell line, is the cell line designated SL0003, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6231.

In one embodiment, the present invention provides a human cell comprising stably integrated nucleic acid sequences comprising: (a) a first expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said proteins are expressed in said human cell; (b) a second expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E2B polymerase protein, wherein said protein is expressed in said human cell; and (c) a third expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1B-55K and E1B-19K proteins, wherein said proteins are expressed in said human cell. In a particular embodiment, the E1A proteins expressed by the human cell comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. In a preferred embodiment the E1A proteins expressed by the human cell comprise: (a) a first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein (*d/1101*); and (b) a second deletion

corresponding to amino acid residues 111-123 (*d*/1107) of said E1A 289R protein and amino acid residues 111-123 (*d*/1107) of said E1A 243R protein.

The present invention provides the above human cells, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26, the second expression cassette comprises the nucleic acid set forth in SEQ ID NO: 23 and/or the third expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 18. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1, the second expression cassette comprises the nucleic acid set forth in SEQ ID NO: 20 and/or the third expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 19. The present invention also provides the above human cell, wherein the cell is designated SL0006, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6663. In a preferred embodiment of the invention, the recombinant adenovirus production cell line, is the cell line designated SL0006, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6663.

Host cells may be transiently or stably transfected with helper adenovirus nucleic acid sequences utilizing techniques known in the art and/or described herein. Preferably, the helper adenovirus nucleic acid sequences are stably integrated into the nuclear genome of the host cells.

The present invention provides methods for producing a host cell for the production of replication-defective adenovirus comprising transforming or transfecting a cell (preferably, a human cell) with a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (examples of such adenoviral proteins are described below), and the second nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E1B-55K protein (and preferably, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein). The cell may be transformed or transfected with the first and second nucleic acid molecules simultaneously or sequentially in any order. In a specific

embodiment, the cell is transformed or transfected with the first nucleic acid molecule and then the second nucleic acid molecule.

The present invention provides methods for producing a cell for the production of replication-defective adenovirus comprising transforming or
5 transfecting a cell (preferably, a human cell) with a first nucleic acid molecule, a second nucleic acid molecule and a third nucleic acid molecule, wherein the first nucleic acid molecule comprises a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (examples of such adenoviral proteins are described below), the
10 second nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E2b polymerase, and the third nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E1B-55K protein and preferably, a nucleotide sequence encoding an adenoviral E1B-55K protein and E1B-19K protein. The cell may be transformed or transfected with the first, second and third nucleic acid molecules simultaneously or sequentially in any order. In a specific
15 embodiment, the cell is transformed or transfected with the first nucleic acid molecule, the second nucleic acid molecule, and then the third nucleic acid molecule.

In one embodiment, the invention provides a method for producing a human
20 cell for the production of replication-defective adenovirus comprising: (a) transforming a human cell with a first expression cassette, wherein said first expression cassette comprises a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said
25 proteins are expressed in said human cell; and (b) transforming said human cell with a second expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E1B protein, wherein said E1B protein comprises an E1B-55K protein but not an E1B-19K protein, wherein said E1B-55K protein is expressed in said human cell. In a
30 particular embodiment, the E1A proteins encoded by the first expression cassette comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an

E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d*/1108) of an E1A 289R protein and amino acid residues 124-127 (*d*/1108) of an E1A 243R protein. In another embodiment, the E1A proteins encoded by the first expression cassette comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d*/1101) and amino acid residues 4-25 of said E1A 243R protein (*d*/1101); and (b) said second deletion corresponding to amino acid residues 111-123 (*d*/1107) of said E1A 289R protein and amino acid residues 111-123 (*d*/1107) of said E1A 243R protein.

The present invention provides the above methods, wherein the cell is derived from an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above methods, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26 and/or the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 15. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1 and/or the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 2.

In one embodiment, the invention provides a method for producing a human cell for the production of replication-defective adenovirus comprising: (a) transforming a human cell with a first expression cassette, wherein said first expression cassette comprises a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said proteins are expressed in said human cell; (b) transforming said human cell with a second expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E2B polymerase protein, wherein said protein is expressed in said human cell; and (c) transforming said human cell with a third expression cassette comprising a promoter active in

said human cell operably linked to a nucleic acid sequence encoding adenoviral E1B-55K and E1B-19K proteins, wherein said protein is expressed in said human cell. In a particular embodiment, the E1A proteins encoded by the first expression cassette comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d*/1108) of an E1A 289R protein and amino acid residues 124-127 (*d*/1108) of an E1A 243R protein. In another embodiment, the E1A proteins encoded by the first expression cassette comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d*/1101) and amino acid residues 4-25 of said E1A 243R protein (*d*/1101); and (b) said second deletion corresponding to amino acid residues 111-123 (*d*/1107) of said E1A 289R protein and amino acid residues 111-123 (*d*/1107) of said E1A 243R protein.

The present invention provides the above methods, wherein the cell is derived from an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above methods, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 23 and/or the third expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 18. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 20 and/or the third expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 19.

In accordance with the invention, recombinant adenovirus (preferably, recombinant replication-defective adenovirus) may be produced by transfecting a rAd production cell line with a rAd vector to produce of recombinant adenovirus (preferably, recombinant replication-defective adenovirus). In a specific

embodiment, the present invention provides a method for producing recombinant adenovirus comprising culturing a rAd complementing cell line transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); and (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein (and preferably, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein). In a preferred embodiment, the present invention provides a method for producing recombinant adenovirus comprising culturing a rAd complementing cell line transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein, and preferably, an adenoviral E1B-19K protein.

The recombinant adenovirus vectors transfected into rAd production cell lines comprise adenoviral nucleotide sequences and optionally, one or more heterologous nucleotide sequences. In a preferred embodiment, the recombinant adenovirus vectors comprise adenoviral nucleotide sequences that lack any homology to the helper adenovirus nucleic acid sequences. The lack of homology between the adenoviral helper nucleic acid sequences and recombinant adenovirus vectors reduces the possibility of the viral genome recombining to produce replication competent adenovirus. In a preferred embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus. In accordance with this embodiment, the recombinant adenovirus vector may be engineered to comprise a mutated adenovirus genome by, *e.g.*, introducing one or more

mutations in an adenovirus genome (*e.g.*, introducing deletions in one or more coding regions for adenoviral proteins). Preferably, the mutations in the adenovirus genome result in lower levels of expression of adenoviral proteins than wild-type adenovirus. The reduction in adenoviral protein expression reduces the immune response to the adenoviral proteins in a subject.

In a specific embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17) and E1B coding region (*e.g.*, SEQ ID NO: 18), and may include one or more heterologous nucleotide sequences. In another embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), and E2B polymerase coding region (for example, SEQ ID NO: 23), and includes one or more heterologous nucleotide sequences. The heterologous nucleotide sequences can be introduced into any region of the genome (*e.g.*, the amino or carboxy-termini). In a specific embodiment, a heterologous nucleotide sequence is introduced into one of the deleted adenoviral coding regions, such as the E1A or E2B coding region, of the mutated adenoviral genome. In a preferred embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), E2B polymerase coding region (*e.g.*, SEQ ID NO: 23), and E3 coding region, and includes a heterologous nucleotide sequence in the deleted E3 coding region.

In accordance with the invention, the recombinant adenovirus (rAd) vectors comprise an adenoviral genome or a portion thereof obtained and/or derived from any adenoviridae or a combination of adenoviridae. In a preferred embodiment, the recombinant adenovirus vectors comprise an adenoviral genome or portion thereof obtained and/or derived from a human adenoviridae. In another preferred embodiment, the recombinant adenovirus vectors comprise an adenoviral genome

or portion thereof obtained and/or derived from the human adenovirus serotype 2 or 5.

In accordance with the invention, any recombinant adenovirus may be produced and/or propagated utilizing the rAd production cell lines described herein.

5 In the preferred embodiment of the invention, the recombinant adenoviruses are derived from the human adenoviridae. In another preferred embodiment of the invention, the recombinant adenovirus is derived from the human adenovirus serotype 2 or 5. In a specific embodiment, the recombinant adenovirus is a replication-defective adenovirus and comprises a mutated genome with a partial or
10 complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17) and E1B coding region (*e.g.*, SEQ ID NO: 18), and may include one or more additional heterologous genes. In a preferred practice of the invention, the recombinant adenovirus is a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the
15 E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), and E2B polymerase coding region (for example, SEQ ID NO: 23), and includes one or more heterologous nucleotide sequences. The preferred recombinant adenoviruses of the present invention comprise viral DNA sequences that lack any homology with the adenoviral DNA sequences in the rAd production cell line, which
20 reduces the possibility of the viral genome recombining with the cellular DNA to produce RCAs.

In one embodiment, the present invention provides a method for producing and/or propagating recombinant adenoviruses comprising: (a) infecting human cells, said human cells comprising stably integrated nucleic sequences comprising:
25 (i) a first expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said proteins are expressed in said human cell; and (ii) a second expression cassette comprising a promoter active in said human cell operably
30 linked to a nucleic acid sequence encoding an adenoviral E1B protein, wherein said E1B protein comprises an E1B-55K protein but not an E1B-19K protein, wherein

said E1B-55K protein is expressed in said human cell; (b) culturing said infected cells under conditions so as to permit replication of the viral genome in the cells; (c) harvesting said cells; and (d) recovering said recombinant adenovirus, wherein steps (c) and (d) are optional.

5 Also provided is the above method, wherein said E1A proteins comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino
10 acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. Also provided is the above method, wherein said E1A proteins comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said
15 E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein (*d/1101*); and (b) said second deletion corresponding to amino acid residues 111-123 (*d/1107*) of said E1A 289R protein and amino acid residues 111-123 (*d/1107*) of said E1A 243R protein.

20 Also provided are the above methods, wherein said cell is derived from the group consisting of an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above methods, wherein said cells are designated SL0003, deposited with the ATCC under accession number PTA-6231.

25 Also provided are the above methods, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 27; and, the above methods, wherein the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 15. In specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1; and, the above methods, wherein the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 2. Also provided are the above methods,
30 wherein the recombinant adenovirus comprises deletions of the E1A and E1B coding regions. Also provided are the above methods, wherein the recombinant

adenovirus is replication-defective. Also provided are the above methods, wherein the recombinant adenovirus further comprises a heterologous gene.

In one embodiment, the present invention provides a method for producing and/or propagating recombinant adenoviruses comprising: (a) infecting human
5 cells, said human cells comprising stably integrated nucleic sequences comprising:
(i) a first expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, wherein said proteins are expressed in said human cell; (ii) a second
10 expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E2B polymerase protein, wherein said E2B polymerase protein is expressed in said human cell; and (iii) a third expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1B-55K and E1B-19K
15 proteins, wherein said proteins are expressed in said human cell; (b) culturing said infected cells under conditions so as to permit replication of the viral genome in the cells; (c) harvesting said cells; and (d) recovering said recombinant adenovirus, wherein steps (c) and (d) are optional.

Also provided is the above method, wherein said E1A proteins comprise: (a)
20 a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues
25 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. Also provided is the above method, wherein said E1A proteins comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein
30 (*d/1101*); and (b) said second deletion corresponding to amino acid residues 111-

123 (*d*/1107) of said E1A 289R protein and amino acid residues 111-123 (*d*/1107) of said E1A 243R protein.

Also provided are the above methods, wherein said cell is derived from the group consisting of an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above methods, wherein said cells are designated SL0006, deposited with the ATCC under accession number PTA-6663.

Also provided are the above methods, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 27, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 23 and/or the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 18. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 20 and/or the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 19. Also provided are the above methods, wherein the recombinant adenovirus comprises deletions of the E1A, E2b polymerase, and E1B coding regions. Also provided are the above methods, wherein the recombinant adenovirus is replication-defective. Also provided are the above methods, wherein the recombinant adenovirus further comprises a heterologous gene.

The recombinant adenoviruses of the invention can be used *in vitro* to express proteins, polypeptides and peptides of interest. The recombinant adenoviruses of the invention can also be used in gene therapy. Further, the recombinant adenovirus of the present invention may be used to immunize a subject. The antibodies generated against an antigen by immunization with a recombinant adenovirus may be used in diagnostic immunoassays, passive immunotherapy, and the generation of anti-idiotypic antibodies.

The present invention also provides a plasmid system for producing a rAd production cell for the production and/or propagation of recombinant adenovirus. In one embodiment, the invention provides a plasmid system for producing and/or propagating a human cell for the production and/or propagation of recombinant adenovirus comprising in separate containers: (a) a first expression cassette

comprising a promoter active in said human cell operably linked to a nucleic sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (b) a second expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E1B protein, wherein said E1B protein comprises an E1B-55K protein but not an E1B-19K protein. Also provided is the above plasmid system wherein said E1A proteins comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. Further provided is the above plasmid system, wherein said E1A proteins comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein (*d/1101*); and (b) said second deletion corresponding to amino acid residues 111-123 (*d/1107*) of said E1A 289R protein and amino acid residues 111-123 (*d/1107*) of said E1A 243R protein. Also provided are the above plasmid systems, wherein said cell is derived from the group consisting of an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above plasmid systems, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1. Also provided are the above plasmid systems, wherein the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 15. In a specific embodiment, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 2.

The present invention further provides a plasmid system for producing a human cell for the production and/or propagation of recombinant adenovirus

comprising in separate containers: (a) a first expression cassette comprising a promoter active in said human cell operably linked to a nucleic sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (b) a second expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding an adenoviral E2B polymerase protein; and (c) a third expression cassette comprising a promoter active in said human cell operably linked to a nucleic acid sequence encoding adenoviral E1B-55K and E1B-19K proteins. Also provided is the above plasmid system wherein said E1A proteins comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127 (*d/1108*) of an E1A 243R protein. Further provided is the above plasmid system, wherein said E1A proteins comprise: (a) said first deletion corresponding to amino acid residues 4-25 of said E1A 289R protein (*d/1101*) and amino acid residues 4-25 of said E1A 243R protein (*d/1101*); and (b) said second deletion corresponding to amino acid residues 111-123 (*d/1107*) of said E1A 289R protein and amino acid residues 111-123 (*d/1107*) of said E1A 243R protein. Also provided are the above plasmid systems, wherein said cell is derived from the group consisting of an established cell line, a tumor cell line, an A549 cell line, and a HeLa cell line. Also provided are the above plasmid systems, wherein the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 26. In a specific embodiment, the first expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 1. Also provided are the above plasmid systems, wherein the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 23. In a specific embodiment, the second expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 20. Also provided are the above plasmid systems, wherein the third

expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 25. In a specific embodiment, the third expression cassette comprises the nucleic acid sequence set forth in SEQ ID NO: 19.

5 **3.1 Terminology**

As used herein, the term "A549" refers to a human lung carcinoma cell line which is commonly known in the art. In one embodiment, the A549 parental cell line used to produce the E1-complementing cell line is ATCC strain CCL-185.

10 As used herein, the term "adenovirus" refers to viruses of the genus adenoviridae. The term "recombinant adenovirus" refer to viruses of the genus adenoviridae capable of infecting a cell whose viral genomes have been modified through conventional recombinant DNA techniques. The term recombinant adenovirus also includes chimeric (or even multimeric) vectors, *i.e.* vectors constructed using complementary coding sequences from more than one viral
15 subtype.

As used herein, the term "adenoviridae" refers collectively to animal adenoviruses of the genus mastadenovirus including but not limited to human, bovine, ovine, equine, canine, porcine, murine and simian adenovirus subgenera. In particular, human adenoviruses includes the A-F subgenera as well as the
20 individual serotypes thereof. A-F subgenera including but not limited to human adenovirus types 1, 2, 3, 4, 4a, 5, 6, 7, 7a, 7d, 8, 9, 10, 11 (Ad11A and Ad11P), 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34a, 35, 35p, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 91.

As used herein, the term "culturing under conditions to permit replication of
25 the viral genome" means maintaining the conditions for the rAd complementation cell line infected with recombinant adenovirus and/or transfected with rAd vector so as to permit the virus to propagate in the cell. It is desirable to control conditions so as to maximize the number of viral particles produced by each cell. Consequently it will be necessary to monitor and control reaction conditions such
30 as temperature, dissolved oxygen, pH, etc. Commercially available bioreactors such as the CelliGen Plus Bioreactor (commercially available from New Brunswick

Scientific, Inc. 44 Talmadge Road, Edison, NJ) have provisions for monitoring and maintaining such parameters. Optimization of infection, transfection and culture conditions will vary somewhat, however, conditions for the efficient replication and production of virus may be achieved by those of skill in the art taking into
5 consideration, for example, the known properties of the producer cell line, properties of the virus and the type of bioreactor.

As used herein, the terms "a deficiency in a gene" or "a deficiency in a gene function" is a type of mutation which serves to impair or eliminate the function of the gene whose nucleic acid sequences was mutated in whole or in part.

10 As used herein, the term "deficient in binding" refers to a gene product forming a complex with less than 50% of the thermodynamic stability of the complex of the wild type gene product to its substrate under physiological conditions. For example, a 13S gene product which contains a deletion in the p300 binding domain would bind to p300 protein with less than 50% of the
15 thermodynamic stability of the wild-type 13S protein. The thermodynamic stability of binding can readily be determined by conventional assay techniques to determine equilibrium binding constants under physiological conditions.

As used herein, the term "E1A gene" refers to the immediate early gene of the adenovirus genome first transcribed following infection. This genomic
20 sequence represents at least the transcription of five mRNAs encoding the 9S, 10S, 11S, 12S and 13S proteins. The 12S and 13S proteins are expressed in the early phase following infection while the 9S, 10S and 11S proteins are expressed later in the adenovirus cycle. The 12S and 13S proteins have 243 and 289 amino acids, respectively. The 12S and 13S proteins are also known as 243R and 289R
25 proteins, respectively. There are three conserved regions in the E1A genomic sequence referred to as conserved region ("CR")-1, CR2 and CR3. CR1 represents amino acids 41-80 of the 12S and 13S proteins. CR2 represents amino acids 121-139 of the 12S and 13S sequence.

GenBank® deposits of the complete human adenovirus type 5 genome are
30 available, see for example, AY339865 and AC 000008. The human adenovirus type 5, 289R, wild type, amino acid sequence is defined by SEQ ID NO: 4. The human

adenovirus type 5, 243R, wild type, amino acid sequence is defined by SEQ ID NO: 6. GenBank[®] deposits of the human adenovirus type 5, 289R, wild type, amino acid sequence are also available, see, for example, AP 000197, AY339865 and AC 00008. GenBank[®] deposits of the human adenovirus type 5, 243R, wild type, amino acid sequence are also available, see, for example, AY339865.

As used herein, the term "expression cassette" is used herein to define a nucleotide sequence capable of directing the transcription and translation of a heterologous coding sequence and the heterologous coding sequence to be expressed. An expression cassette comprises a regulatory element operably linked to a heterologous coding sequence so as to achieve expression of the protein product encoded by said heterologous coding sequence in the cell.

As used herein, the term "helper adenovirus nucleic acid sequence(s)" refers to a nucleic acid sequence(s) that: (i) provides viral functions for the replication of a recombinant adenovirus vector and/or its packaging into infectious virions; and (ii) is (are) not replicated or assembled into viral particles to a measurable degree.

As used herein, the term "heterologous" in the context of nucleic acid sequences, amino acid sequences and antigens refers to nucleic acid sequences, amino acid sequences and antigens that are foreign and are not naturally found associated with a particular adenovirus.

As used herein, the term "infecting" means exposing the recombinant adenovirus to the rAd production cell line under conditions so as to facilitate the infection of the producer cell with the recombinant adenovirus. In cells which have been infected by multiple copies of a given virus, the activities necessary for viral replication and virion packaging are cooperative. Thus, it is preferred that conditions be adjusted such that there is a significant probability that the cells are multiply infected with the virus. An example of a condition which enhances the production of virus in the cell is an increased virus concentration in the infection phase. However, it is possible that the total number of viral infections per cell can be overdone, resulting in toxic effects to the cell. Consequently, one should strive to maintain the infections in the virus concentration in the range of 10^6 to 10^{10} , preferably about 10^9 , virions per ml. Chemical agents may also be employed to

increase the infectivity of the cell line. For example, the present invention provides a method to increase the infectivity of cell lines for viral infectivity by the inclusion of a calpain inhibitor. Examples of calpain inhibitors useful in the practice of the present invention include calpain inhibitor 1 (also known as N-acetyl-leucyl-leucyl-norleucinal, commercially available from Boehringer Mannheim). Calpain inhibitor 1
5 has been observed to increase the infectivity of cell lines to recombinant adenovirus.

As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid sequence is
10 "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the nucleotide sequences being linked are typically contiguous. However, as enhancers generally function when separated from the promoter by
15 several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not directly flanked and may even function in trans from a different allele or chromosome.

As used herein, the term "p300 protein family members" refers the proteins which associate with the amino terminus of E1A including p300 and CBP. In
20 particular p300 co-activates the activity of the transactivating genes, Myb and C/EBP (Mink, *et al.* (1997) Molecular and Cellular Biology 17:6609-6617). The human p300 protein is known in the art and is publicly available from the Swiss-Prot database under accession number Q09472, its corresponding mRNA is available from GenBank under accession number U01877 deposited June 6, 1994
25 and is described in Eckner, *et al.* (1994) Genes Dev. 8:869-884.

As used herein, the term "regulatory element" refers to promoters, enhancers, transcription terminators, insulator regions, silencing region, polyadenylation sites, and the like. The term "promoter" is used in its conventional sense to refer to a nucleotide sequence at which the initiation and rate of
30 transcription of a coding sequence is controlled. The promoter contains the site at which RNA polymerase binds and also contains sites for the binding of regulatory

factors (such as repressors or transcription factors). Promoters may be naturally occurring or synthetic. When the vector to be employed is a viral vector, the promoters may be endogenous to the virus or derived from other sources. The regulatory elements may be arranged so as to allow, enhance or facilitate expression of the transgene only in a particular cell type. For example, the expression cassette may be designed so that the transgene is under control of a promoter which is constitutively active, or temporally controlled (temporal promoters), activated in response to external stimuli (inducible), active in particular cell type or cell state (selective) constitutive promoters, temporal viral promoters or regulatable promoters.

As used herein, the term "recombinant adenovirus vector(s)" refers to a vector construct comprising adenoviral nucleotide sequences and optionally, one or more heterologous nucleotide sequences. In a preferred embodiment, the recombinant adenovirus vectors comprise adenoviral nucleotide sequences that lack any homology to the helper adenovirus nucleic acid sequences. In another preferred embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus. In accordance with this embodiment, the recombinant adenovirus vector may be engineered to comprise a mutated adenovirus genome by, *e.g.*, introducing one or more mutations in an adenovirus genome (*e.g.*, introducing deletions in one or more coding regions for adenoviral proteins).

As used herein, the terms, "rAd production cell line", "rAd complementation cells", and "rAd complementation cell lines" are synonyms and mean a cell able to propagate recombinant adenoviruses by providing viral functions for replication of a recombinant adenovirus and/or its packaging into infectious virions.

As used herein, the term "Rb protein family members" refers to the retinoblastoma gene product (p105), p107 and p130. The retinoblastoma gene is well characterized in the art. The amino acid sequence of human Rb is available from GenBank under accession Number 190959 deposited July 12, 1995 and the mRNA sequence is available from GenBank under accession number M15400 and is described in Lee, *et al.* (1988) PNAS (USA) 85:6017-6021.

As used herein, the term "stably integrated" means, with respect to an exogenous nucleic acid sequence, that such sequence is integrated into the genome of the cell such that successive generations of the cell retains the exogenous nucleic acid sequence.

5 As used herein, the term "transfection" or "transformation" means the introduction of a nucleic acid into a cell. A host cell that receives the introduced DNA or RNA has been "transformed" and is a "transformant" or a "clone." Examples of transformation methods which are very well known in the art include liposome delivery, electroporation, CaPO₄ transformation, DEAE-Dextran
10 transformation, microinjection and viral infection.

As used herein, the term "transformation" may also refer to, in the context of *in vitro* animal cell culture, a permanent alteration of the cell phenotype that is presumed to occur *via* an irreversible genetic change. A "transformed cell" usually is a cell that, among other potential phenotypic characteristics, has an infinite or a
15 significantly (or greatly) extended lifespan when compared with the cells of the finite or primary cell line from which it arose. The context in which the term is used will govern the meaning.

4. BRIEF DESCRIPTION OF THE FIGURES

20 Figure 1 is a schematic diagram of the functional domains of the 243R and 289R E1A proteins. Regions required for binding of the cellular proteins p300/CBP and pRb are indicated as are domains necessary for activation of cellular apoptosis, induction of cell cycle progression in quiescent cells and transcriptional activation of the adenovirus early gene regions.

25 Figure 2. Plasmid map of pRcRSV-E1Adl01/07.

RSV promoter: Start:209 End:605

BGH poly A signal: Start:1556 End:1782

f1 origin: Start:1838 End:2360

SV40 promoter: Start:2422 End:2747

30 SV40 origin: Start:2616 End:2701

Neomycin resistance gene: Start:2753 End:3547

SV40 poly A signal: Start:3551 End:3760

pUC19 sequence (448-2622): Start:3900 End:6074

Col E1 origin: Start:4083 End:4606

Ampicillin resistance gene: complement(5090..5950)

5 E1A 12S CDS N-term: Start:633 End:944

E1A proteins start (ATG): Start:633 End:635

E1A 13S CDS N-term: Start:633 End:1082

Splice donor for E1A 12s mRNA: Start:942 End:942

Splice donor for E1A 13s mRNA: Start:1080 End:1080

10 E1A 12S/13S CDS C-term CDS: Start:1199 End:1513

Stop TAA for E1A 32k/27k: Start:1511 End:1513

dl1101 mutation (amino acids 4-25 of WT are deleted): Start:644 End:645

dl1107 mutation (amino acids 111-123 of WT are deleted): Start:896

End:897

15

Figure 3. Plasmid map of pcDNA3.1(+)-E1B-55k Hygro.

CMV promoter: Start: 209 End: 863

T7 promoter/priming site: Start:863 End: 882

pcDNA3.1 BGH reverse priming site: Start:2470 End:2487

20 BGH poly A signal: Start:2469 End:2683

f1 origin: Start:2746 End:3159

SV40 promoter and origin: Start:3224 End:3548

Hygromycin resistance gene CDS: Start:3566 End:4589

SV40 early poly A signal: Start:4602 End:4974

25 pMB1 (pUC derived) origin: complement(5234..5904)

Ampicillin resistance gene: complement(6049..6909)

E1B 55K (495R) CDS: Start:942 End:2430

30 Figure 4. Plasmid map of pVITRO21RESPuroE1b: Plasmid encoding the entire E1b and pIX coding sequence driven by the human ferritin heavy subunit

promoter and SV40 enhancer with a puromycin resistance gene for cell selection following an IRES element downstream of the adenovirus sequence.

Figure 5. Plasmid map of pMGCMVE2Bpol. Plasmid using a CMV promoter to drive expression of the full-length E2b polymerase coding sequence, followed by an IRES sequence and the hygromycin resistance gene which was used for selection.

Figure 6. Schematic representation of viral constructs. Similarities and differences between viral constructs in the E1, E2b, and E3 regions are indicated. CMV-GFP expression cassettes are inserted in the E1 region for GFCB and CGAB viruses, and as 5' to 3' orientation inserts in the E3 region for 42GC, 2GCP, and 46GC. CONG has expression cassettes in both the E1 and E3 regions as indicated. The 2GCP construct has a deletion in the E2b viral DNA polymerase region which prevents its expression. Further details can be found in Example 2.

Figure 7. Expression of E2b polymerase in cells and effect on viral productivity of E2b polymerase deleted virus. Panel A) Western analysis of E2b polymerase protein from cellular lysates of isolated clones 3C4, 3C9 and 3D8 relative to non E2b polymerase complementing parental clone 4 and unmodified A549 cells. Lower portion of Western shows detection of β -actin protein, verifying equal total protein loading per lane. Panel B) Virus particles produced per cell infected with the E2b polymerase deleted 2GCP virus. Results plotted are from duplicate 10 cm plates of the indicated clones infected with 5×10^8 P/ml of purified 2GCP virus +/- standard deviation.

Figure 8. E1b complementation and effects on viral productivity. Panel A) Pictures of GFP fluorescence from individual clones infected with either 5×10^8 P/ml of GFCB or CONG virus at 48 hours post-infection. Panel B) The ratio of GFP fluorescence as determined by Cytofluor analysis from CONG infected cells over the fluorescence from the same clone infected with GFCB virus is plotted. Panel C)

31.

Virus particles produced per cell from the indicated clones infected with 5×10^8 P/ml of purified 2GCP virus +/- standard deviation.

5 Figure 9. Virus productivity in different cell lines and stability of clone 15M15. Panel A) Virus particles produced per cell from either parental clone 3D8 (no E1b complementation), selected clone 15M15 (with E1b complementation) or C7 cells (293 based, E2b polymerase complementing). Results plotted are from duplicate 10 cm plates of the indicated clones infected with 5×10^8 P/ml of purified
10 2GCP virus +/- standard deviation. Panel B) Viral productivity from clone 15M15. Cells were infected and harvested after 1, 5 or 10 passages of growth either in selection mix media containing hygromycin, puromycin and G418 or regular growth media without the selection drugs. Cells were infected with 2GCP virus at either 2×10^9 or 1×10^9 P/ml virus as indicated. Results are plotted from each sample as
15 virus particles / cell. Panel C) E1a and E2b polymerase protein expression. Parallel infections as outlined in Panel B were harvested, and the levels of E1a and E2b polymerase protein from cellular lysates were analyzed by Western analysis. Samples were loaded at equal total protein concentration per well based on
20 Bradford assay results.

Figure 10. Late Ad gene expression from infected cells. Panels A-D show the levels of hexon and fiber expressed from infected cells and detected by Western analysis. Panel A) Clone 15M15 production cell line. Panel B) Non-complementing CHO cell line. Panels C) and D) Partial E1a function complementing
25 cell lines Hela and HepG2, respectively. Virus designation: G=GFCB, C=CGAB, 4=42GC, 2=2GCP, 6=6GCP, U =uninfected, L=ladder.

Figure 11. *In Vitro* GFP Expression. Panels (A)-(D) GFP expression from HOF or Saos2 cells over time after infection with 5×10^8 P/ml CGAB, 42GC, or
30 2GCP viruses. Graphs plot Cytofluor quantitation of GFP expression from duplicate infected wells +/- standard deviation, while photographs of infected cells 8 days post-infection are shown on the right. Panels (E)-(F) GFP expression from infected CHO

cells as in Panels Band -D. Graphs plot Cytofluor quantitation of GFP expression from duplicate infected wells +/- standard deviation, while photographs above show infected cells 15 days post-infection.

5

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides, *inter alia*, rAd production cell lines, methods for producing the rAd production cell lines, and methods for producing recombinant adenoviruses using the rAd production cell lines.

10 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained in the literature. See, *e.g.*, Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook, *et al.*, 1989"); DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 15 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. (1985)); Transcription And Translation (B.D. Hames & S.J. Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning (1984); F.M. Ausubel, *et al.* (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994). 20

5.1 Helper Adenovirus Nucleic Acid Sequences

25 The helper adenovirus nucleic acid sequences of the present invention: (i) provide viral functions for the replication of a recombinant adenovirus construct and/or its packaging into infectious virions; and (ii) are not replicated or assembled into viral particles to a measurable degree. The helper adenovirus nucleic acid sequences can be obtained and/or derived from any adenoviridae or a combination 30 of adenoviridae. In a preferred embodiment, the helper adenovirus nucleic acid sequences are obtained and/or derived from a human adenoviridae. In another preferred embodiment, the helper adenovirus nucleic acid sequences are obtained

and/or derived from human adenovirus serotype 2 or 5. The nucleic acid sequences for adenovirus proteins can be obtained, *e.g.*, from the GenBank database or a database like it, literature publications, or by routine cloning and sequencing.

5 In one embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E1B protein(s), such as E1B-55K and/or E1B-19K. In accordance with this embodiment, the helper adenovirus nucleic acid sequences may also include one, two or more of the following: (i) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E2 protein(s); (ii) a nucleic acid molecule(s) comprising a nucleotide sequence(s) encoding an adenoviral E4 protein(s); and/or (iii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral L4 100K protein. Non-limiting examples of adenoviral E2 proteins include E2A binding protein, E2B polymerase, E2B pre-terminal protein, and E2B IVa2 protein. Non-limiting examples of adenoviral E4 proteins include those encoded by open reading frame (ORF)-6, ORF3, and ORF6/7. Table 1 provides examples of the nucleotide and amino acid sequences of human adenovirus serotype 5 E1A proteins, E1B-55K protein, E1B-19K protein and E2B polymerase protein.

15 In certain embodiments, the helper adenovirus nucleic acid sequence includes a nucleic acid molecule comprising: (i) a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleotide sequence(s) encoding an adenoviral E1B protein(s), such as E1B-55K and/or E1B-19K. In accordance with these embodiments, the nucleic acid sequence may also include one, two or more of the following: (i) a nucleotide sequence(s) encoding an adenoviral E2 protein(s); (ii) a nucleotide sequence(s) encoding an adenoviral E4 protein(s); and/or (iii) a nucleotide sequence encoding an adenoviral L4 100K protein.

In certain embodiments, a helper adenovirus nucleic acid sequence encodes a fusion or chimeric protein product comprising an adenoviral protein joined via a peptide bond to a heterologous protein sequence. Such chimeric products can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acids to each other by methods known in the art, in the proper coding frame, and expressing the chimeric products in a suitable host by methods commonly known in the art.

In a specific embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B protein, wherein the E1B protein comprises an E1B-55K protein but not an E1B-19K protein. In another preferred embodiment, the helper adenovirus nucleic acid sequences include: (i) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (iii) a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins.

The nucleotide sequence(s) encoding the adenovirus mutant E1A proteins, which is utilized as a helper adenovirus nucleic acid sequence in accordance with the present invention, provides only the required functions for producing high levels of E1-deleted adenovirus vectors. More specifically, the nucleotide sequence(s) encodes E1A proteins that are defective for binding to the cellular proteins p300/CBP and pRb but still carry the wild-type CR3 domain which transactivates early viral promoters required for the initial phase of lytic growth. The use of such a nucleotide sequence overcomes the toxicity associated with wild-type adenoviral E1A proteins in tumor cells.

The rationale for using nucleotide sequences encoding E1A proteins defective in p300 and pRb binding is based, in part, on mapping studies that have

separated the E1A functions required for induction of cellular DNA synthesis and activation of the early adenovirus transcription units. The ability of the E1A adenoviral proteins to activate the early transcription units is required in all production cell lines for successful productive infection, but the ability of the E1A to induce the cell cycle may not be required in established cell lines that divide continuously. The nucleotide sequences encoding the mutated adenovirus E1A proteins described herein retain the ability to activate transcription, but are defective for induction of cellular DNA synthesis. The adenoviral E1A regions required for stimulation of cellular DNA synthesis may also be responsible for induction of apoptosis and this may hinder successful establishment of E1-complementing cell lines.

To produce E1A proteins that are defective for binding to the cellular proteins p300/CBP and pRb, mutations in the E1A 289R and E1A 243R coding regions can be introduced. In a specific embodiment, deletions in the E1A 289R and E1A 243 coding regions are introduced to achieve a reduction in the binding of p300 and pRb family members to E1A proteins. Preferably, the deletions in the E1A 289R and the E1A 243R coding sequences necessary to achieve reduction of p300 and pRb binding are as minimal as possible to prevent major disruption of the secondary and tertiary structure of the E1A 289R and the E1A 243R proteins.

In order to eliminate p300 binding it is preferred that a mutation be introduced in the nucleotide sequence encoding the p300 binding domains of E1A 289R and E1A 243R. The p300 binding domain of the E1A-12S and 13S proteins has been narrowed to the first 69 amino acids (Egan, *et al.* (1988) Mol. Cell Biol. 8:3955-3959). However, it has been shown that amino acids 26 to 35 are not necessary for p300 binding. There are two regions of p300 binding in the 12S and 13S molecules from approximately amino acid residues 4-25 and amino acid residues 36-49. Elimination of one or both is sufficient to disrupt p300 binding. Preferably, the elimination of amino acid residues 4-25 is employed to eliminate the p300 binding function. Deletions of less than about 30 amino acids in the C-terminal region to eliminate p300 binding are preferred, although smaller modifications are more preferred. In a specific embodiment, deletions in the C-

terminal region to eliminate p300 binding are 25 amino acids or less, 20 amino acids or less, 15 amino acids or less, or 10 amino acids or less. The deletion of amino acid residues 4-25 of the 289R and the 243R proteins are sufficient to disrupt p300 binding without affecting transactivational functions of CR3. The
5 "transactivating function of the CR3 domain" refers to the ability of the products of the E1A gene to activate transcription of promoters later in the viral cycle such as E1B and E3. The CR3 region is functionally present only in the 13S protein and represents amino acids 140 to 188. The transactivating function of the E1A gene product is contained in the CR3 region. Alternatively preferred are a deletion of
10 amino acids from amino acid residue 30 to amino acid residue 49 (*d/1103*) and more particularly amino acid residue 36 to amino acid residue 49 to eliminate p300 binding.

Point mutations sufficient to disrupt binding p300 are particularly preferred. For example, a point mutation of the second amino acid from arginine to glycine
15 (Arg2 to Gly2) in the 289R protein has been demonstrated to disrupt p300 binding (See *e.g.*, pm563, Whyte, *et al.*, (1989) Cell 56:67-75).

The Rb-105 binding domain of the E1A-12S and 13S proteins has been characterized as located within amino acids 111-127. Similarly, in regard to eliminating pRb105 binding, minimal modifications are preferred. In a specific
20 embodiment, deletions in the pRb binding domain of less than 20 amino acids, 15 amino acids or less, 10 amino acids or less are introduced. Elimination of selective amino acids in the pRb105 binding domain such as amino acid 111-123 (*d/1107*) and amino acids 124-127 (*d/1108*) are preferred. In an embodiment, the mutation set forth by Moran *et al.* (pm928 (C124G)) is used to disrupt pRb105 binding
25 ((1986) Mol Cell Biol. 6(10):3470-3480).

In a specific embodiment, a nucleic acid molecule comprising a nucleotide sequence encoding the adenoviral E1A mutant E1A*d/01/07* protein is utilized as a helper adenovirus nucleic acid sequence. The E1A*d/01/07* protein is defective for binding to the cellular proteins p300/CBP and pRb but still carries the wild-type CR3
30 domain which transactivates early viral promoters required for the initial phase of lytic growth. It has mutations affecting the ability of the adenoviral E1A protein to

induce cellular DNA synthesis and apoptosis but still carries the wild-type CR3 domain which transactivates early viral promoters required for the initial phase of lytic growth (Winberg and Shenk, (1984) EMBO J. 3:1907-1912).

Helper adenovirus nucleic acid sequences may be propagated in microorganisms, for example, as part of a bacterial plasmid or bacteriophage. A nucleotide sequence encoding an adenoviral protein may be incorporated into a recombinant plasmid, bacteriophage, etc. by methods well known in the art.

In a specific embodiment, a nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral protein is operably linked to a regulatory element. In a particular embodiment, the nucleotide sequence encoding an adenoviral protein is inserted into an appropriate expression vector, *i.e.*, a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. The necessary transcriptional and translational signals can be supplied by the native promoter of the adenoviral protein and/or a heterologous promoter. Any method available in the art can be used for the insertion of a nucleotide sequence into a vector to construct expression vectors containing appropriate transcriptional/translational control signals and protein coding sequences.

In one embodiment, each nucleotide sequence encoding an adenoviral protein is inserted into an expression vector. In alternative embodiment, two or more nucleotide sequences encoding adenoviral proteins are inserted into one expression vector.

In a specific embodiment, a vector is used that comprises a promoter operably linked to a nucleotide sequence encoding an adenoviral protein, one or more origins of replication, and optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene). In accordance with this embodiment, a promoter can be any promoter known to the skilled artisan. For example, the promoter can be a constitutive promoter, a tissue-specific promoter or an inducible promoter. Examples of promoters that may be used in accordance with the invention include: the SV40 early promoter (Bemoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus

(Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), the beta-actin promoter, the CMV promoter, the SR-alpha promoter, the hFer/SV40 promoter, the RSV promoter, the Elf-1 promoter, the Tet promoter, the Ecdyson promoter and a rapamycin promoter.

In a specific embodiment, a native promoter is utilized to regulate the expression of a nucleotide sequence encoding an adenoviral protein. In alternative embodiment, a promoter that is not native to the adenoviral gene encoding the protein being expressed (*i.e.*, a heterologous promoter) is utilized to regulate the expression of the protein. In certain embodiments, the promoter is a constitutive promoter (*e.g.*, a viral, cellular or hybrid constitutive promoter). In other embodiments, the promoter is an inducible promoter. In yet other embodiments, the promoter is a tissue-specific promoter.

In certain embodiments, it is desirable to use a constitutive promoter, such as a CMV promoter, beta-actin promoter, SR-alpha promoter or hFer/SV40 promoter, to regulate the expression of a nucleotide sequence encoding one or more of the following proteins: E1B proteins, E2A proteins and/or E2B proteins. In certain other embodiments, it is desirable to use a constitutive promoter, such as a RSV promoter, SV40 promoter or Elf-1 promoter, to regulate the expression of a nucleotide sequence encoding one or more of the following proteins: E1A proteins and/or E4 proteins. In yet other embodiments, it is desirable to use an inducible promoter, such as a Tet promoter or Ecdyson promoter, to regulate the expression of L4 100K.

Expression vectors containing the nucleotide sequences of interest can be identified by three general approaches: (1) nucleic acid hybridization, (2) presence or absence of "marker" gene function, and (3) expression of the inserted sequences. In the first approach, coding sequences can be detected by nucleic acid hybridization to probes comprising sequences homologous and complementary to the inserted sequences. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of

certain "marker" functions (*e.g.*, resistance to antibiotics, occlusion body formation in baculovirus, etc.) caused by insertion of the sequences of interest in the vector. For example, if a nucleotide sequence encoding an adenoviral protein, or portion thereof, is inserted within the marker gene sequence of the vector, cells
5 transfected with the encoded protein or portion will be identified by the absence of the marker gene function (*e.g.*, loss of beta-galactosidase activity). In the third approach, expression vectors can be identified by assaying for the adenoviral protein expressed by the recombinant vector. Such assays can be based, for example, on the physical or functional properties of the interacting species in *in*
10 *vitro* assay systems, *e.g.*, binding to an antibody.

The helper adenovirus nucleic acids may be incorporated into a cell line, thus bypassing the need to cotransfect helper adenovirus nucleic acid sequences and recombinant adenovirus vector sequences. Instead, transfection of the helper
adenovirus nucleic acid sequence-containing cell line with recombinant adenovirus
15 vector would directly result in production of recombinant adenovirus. The present invention provides for such cell lines. See Section 5.3, *infra*.

5.2 Recombinant Adenovirus Constructs

The recombinant adenovirus vectors of the invention comprise adenoviral
20 nucleotide sequences and optionally, one or more heterologous nucleotide sequences. In a preferred embodiment, the recombinant adenovirus vectors comprise adenoviral nucleotide sequences that lack of homology to the helper adenovirus nucleic acid sequences. The lack of homology between the adenoviral helper nucleic acid sequences and recombinant adenovirus vectors reduces the
25 possibility of the viral genome recombining to produce replication competent adenovirus. In a preferred embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus. In accordance with this embodiment, the recombinant adenovirus vector may be engineered to comprise a mutated adenovirus genome by, *e.g.*, introducing one or more mutations in an adenovirus
30 genome (*e.g.*, introducing deletions in one or more coding regions for adenoviral proteins). Preferably, the mutations in the adenovirus genome result in lower

levels of expression of adenoviral proteins than wild-type adenovirus. The reduction in adenoviral protein expression reduces the immune response to the adenoviral proteins in a subject.

In a specific embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17) and E1B coding region (*e.g.*, SEQ ID NO: 18), and may include one or more heterologous nucleotide sequences. In another embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), and E2B polymerase coding region (for example, SEQ ID NO: 23), and includes one or more heterologous nucleotide sequences. The heterologous nucleotide sequences can be introduced into any region of the genome (*e.g.*, the amino or carboxy-termini). In a specific embodiment, a heterologous nucleotide sequence is introduced into one of the deleted adenoviral coding regions, such as the E1A or E2B coding region, of the mutated adenoviral genome. In a preferred embodiment, the recombinant adenovirus vector encodes a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, a complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), E2B polymerase coding region (*e.g.*, SEQ ID NO: 25), and E3 coding region, and includes a heterologous nucleotide sequence in the deleted E3 coding region.

In accordance with the invention, the recombinant adenovirus (rAd) vectors comprise an adenoviral genome or a portion thereof obtained and/or derived from any adenoviridae or a combination of adenoviridae. In a preferred embodiment, the recombinant adenovirus vectors comprise an adenoviral genome or portion thereof obtained and/or derived from a human adenoviridae. In another preferred embodiment, the recombinant adenovirus vectors comprise an adenoviral genome or portion thereof obtained and/or derived from the human adenovirus serotype 2 or 5.

The rAd vector of the present invention may incorporate any heterologous nucleotide sequence, including genes or portions of genes. It may be desirable to incorporate a gene with a readily detectable product (known in the art as a marker, recorder, or reporter gene) as part of the rAd vector although the invention is not limited to such constructs. Non-limiting examples of reporter genes include beta-galactosidase, neomycin phospho-transferase, chloramphenicol acetyltransferase, thymidine kinase, luciferase, beta-glucuronidase, and xanthine-guanine phosphoribosyl transferase, to name but a few.

In an embodiment of the invention, the heterologous nucleotide sequence is obtained and/or derived from a source other than the rAd vector. In certain embodiments, the heterologous nucleotide sequence encodes an antigenic protein, a polypeptide or peptide of a virus belonging to a different species, subgroup or variant of adenovirus other than the species, subgroup or variant from which the rAd vector is derived. In other embodiments, the heterologous nucleotide sequence is not viral in origin. In accordance with these embodiments, the heterologous nucleotide sequence may encode a moiety, peptide, polypeptide or protein possessing a desired biological property or activity. Such a heterologous nucleotide sequence may encode a tag or marker. Such a heterologous nucleotide sequence may encode a biological response modifier, examples of which include, interleukins, hormones and growth factors.

In certain embodiments, the heterologous nucleotide sequence encodes an antigenic protein, polypeptide or peptide obtained and/or derived from a virus other than an adenovirus. Non-limiting examples of such viruses from the following families: adenoviridae (*e.g.*, arenavirus, lymphocytic choriomeningitis virus, Ippu virus, and lassa virus), arterivirus (*e.g.*, equine arteritis virus), astroviridae (*e.g.*, astrovirus), bunyaviridae (*e.g.*, bunyavirus, bunyamwera virus, hantavirus, Crimean-congo hemorrhagic fever virus, phlebovirus, and Rift Valley fever complex), caliciviridae (*e.g.*, calicivirus), Coronaviridae (*e.g.*, coronavirus, torovirus and SARS), deltavirus, filoviridae (*e.g.*, filovirus, Marburg virus and Ebola virus Zaire), flaviviridae (*e.g.*, flavivirus, yellow fever virus, tick-borne encephalitis virus group, Japanese encephalitis Group, pestivirus and hepatitis C virus),

hepadnaviridae (*e.g.*, hepatitis B virus), herpesviridae (*e.g.*, human herpesvirus 1, varicellovirus, human herpesvirus 3, cytomegalovirus, human herpesvirus 5, roseolovirus, human herpesvirus 6, and human herpesvirus 4), orthomyxoviridae (*e.g.*, influenza virus A, B and C), papovaviridae (*e.g.*, papillomavirus),

5 paramyxoviridae (*e.g.*, paramyxovirus, human parainfluenza virus 1, morbillivirus, measles virus, rubulavirus, mumps virus, pneumovirus and human respiratory syncytial virus), parvoviridae (*e.g.*, parvovirus and adeno-associated virus (AAV)), picornaviridae (*e.g.*, enterovirus, human poliovirus 1, rhinovirus, hepatovirus, human hepatitis A virus, cardiovirus, encephalomyocarditis virus, aphthovirus and

10 foot-and-mouth disease virus O), poxviridae (*e.g.*, vaccinia virus, fowlpox virus and myxoma virus), reoviridae (*e.g.*, reovirus, rotavirus, coltivirus, cypovirus, and fijivirus), retroviridae (*e.g.*, murine leukemia virus, human T lymphocyte leukemia (HTLV)-1 and 2, and lentivirus such as human immunodeficiency virus 1, human immunodeficiency virus 2, and simian immunodeficiency virus), rhabdoviridae (*e.g.*,

15 vesiculovirus, lyssavirus and rabies virus), and togaviridae (*e.g.*, Sindbis virus, Rubivirus and Rubella virus). See, *e.g.*, Fields et al., (ed.), 1991, Fundamental Virology, Second Edition, Raven Press, New York, for a description of viruses and viral antigens.

In certain embodiments, the heterologous nucleotide sequence encodes an

20 antigenic protein, polypeptide or peptide of obtained and/or derived from a bacteria, fungi, and/or other pathogen or parasite. Examples of heterologous nucleotide sequences obtained and/or derived from bacteria include, but are not limited to, nucleotide sequences encoding antigens derived from species of the following genera: *Salmonella*, *Shigella*, *Chlamydia*, *Helicobacter*, *Yersinia*,

25 *Bordatella*, *Pseudomonas*, *Neisseria*, *Vibrio*, *Haemophilus*, *Mycoplasma*, *Streptomyces*, *Treponema*, *Coxiella*, *Ehrlichia*, *Brucella*, *Streptobacillus*, *Fusospirocheta*, *Spirillum*, *Ureaplasma*, *Spirochaeta*, *Mycoplasma*, *Actinomycetes*, *Borrelia*, *Bacteroides*, *Trichomonas*, *Branhamella*, *Pasteurella*, *Clostridium*, *Corynebacterium*, *Listeria*, *Bacillus*, *Erysipelothrix*, *Rhodococcus*, *Escherichia*,

30 *Klebsiella*, *Pseudomonas*, *Enterobacter*, *Serratia*, *Staphylococcus*, *Streptococcus*, *Legionella*, *Mycobacterium*, *Proteus*, *Campylobacter*, *Enterococcus*, *Acinetobacter*,

Morganella, *Moraxella*, *Citrobacter*, *Rickettsia*, *Rochlameae*, as well as bacterial species such as: *P. aeruginosa*; *E. coli*, *P. cepacia*, *S. epidermis*, *E. faecalis*, *S. pneumonias*, *S. aureus*, *N. meningitidis*, *S. pyogenes*, *Pasteurella multocida*, *Treponema pallidum*, and *P. mirabilis*.

5 Examples of heterologous nucleotide sequences derived from fungi, include, but are not limited to, nucleotide sequences encoding antigens obtained and/or derived from fungi such as *Cryptococcus neoformans*, *Blastomyces dermatitidis*, *Aiellomyces dermatitidis*, *Histoplasma capsulatum*; *Coccidioides immitis*, *Candida* species, including *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. guilliermondii* and *C.*
 10 *krusei*, *Aspergillus* species, including *A. fumigatus*, *A. flavus* and *A. niger*, *Rhizopus* species, *Rhizomucor* species, *Cunninghammella* species, *Apophysomyces* species, including *A. saksenaea*, *A. mucor* and *A. absidia*; *Sporothrix schenckii*, *Paracoccidioides brasiliensis*, *Pseudallescheria boydii*, *Torulopsis glabrata*; *Trichophyton* species, *Microsporum* species and *Dermatophyres* species, as well as
 15 any other yeast or fungus now known or later identified to be pathogenic.

Finally, examples of heterologous nucleotide gene sequences obtained and/or derived from parasites include, but are not limited to, nucleotide sequences encoding antigens derived from members of the *Apicomplexa* phylum such as, for example, *Babesia*, *Toxoplasma*, *Plasmodium*, *Eimeria*, *Isospora*, *Atoxoplasma*,
 20 *Cystoisospora*, *Hammondia*, *Besnotia*, *Sarcocystis*, *Frenkelia*, *Haemoproteus*, *Leucocytozoon*, *Theileria*, *Perkinsus* and *Gregarina* spp.; *Pneumocystis carinii*; members of the *Microspora* phylum such as, for example, *Nosema*, *Enterocytozoon*, *Encephalitozoon*, *Septata*, *Mrazekia*, *Amblyospora*, *Ameson*, *Glugea*, *Pleistophora* and *Microsporidium* spp.; and members of the *Ascetospora* phylum such as, for
 25 example, *Haplosporidium* spp., as well as species including *Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malaria*; *Toxoplasma gondii*; *Leishmania mexicana*, *L. tropica*, *L. major*, *L. aethiopica*, *L. donovani*, *Trypanosoma cruzi*, *T. brucei*, *Schistosoma mansonii*, *S. haematobium*, *S. japonium*; *Trichinella spiralis*, *Wuchereria bancrofti*; *Brugia malayi*; *Entamoeba histolytica*; *Enterobius vermicularis*, *Taenia solium*, *T.*
 30 *saginata*, *Trichomonas vaginatis*, *T. hominis*, *T. tenax*; *Giardia lamblia*; *Cryptosporidium parvum*; *Pneumocystis carinii*, *Babesia bovis*, *B. divergens*, *B.*

microti, *Isospora belli*, *L. hominis*, *Dientamoeba fragilis*, *Onchocerca volvulus*, *Ascaris lumbricoides*, *Necator americanis*, *Ancylostoma duodenale*, *Strongyloides stercoralis*, *Capillaria philippinensis*, *Angiostrongylus cantonensis*, *Hymenolepis nana*, *Diphyllobothrium latum*, *Echinococcus granulosus*, *E. multilocularis*,
 5 *Paragonimus westermani*, *P. caliensis*, *Chlonorchis sinensis*, *Opisthorchis felinae*, *G. Viverini*, *Fasciola hepatica*, *Sarcoptes scabiei*, *Pediculus humanus*, *Phthirus pubis*, and *Dermatobia hominis*, as well as any other parasite now known or later identified to be pathogenic.

Other heterologous nucleotide sequences of the present invention include
 10 nucleotide sequences encoding antigens that are characteristic of an autoimmune disease. These antigens will typically be derived from the cell surface, cytoplasm, nucleus, mitochondria and the like of mammalian tissues. Examples of such antigens include, but are not limited to, antigens characteristic of diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, pernicious
 15 anemia, Addison's disease, scleroderma, autoimmune atrophic gastritis, juvenile diabetes, and discoid lupus erythematosus.

In certain embodiments, the heterologous nucleotide sequences of the present invention include antigens that are allergens. Antigens that are allergens generally include proteins or glycoproteins, including antigens derived from pollens,
 20 dust, molds, spores, dander, insects and foods. In other embodiments, the heterologous nucleotide sequences of the present invention include tumor antigens. Tumor antigens typically will be derived from the cell surface, cytoplasm, nucleus, organelles and the like of cells of tumor tissue. Non-limiting examples of tumor antigens include proteins encoded by mutated oncogenes; viral proteins
 25 associated with tumors; and glycoproteins. Tumors include, but are not limited to, those derived from the types of cancer: lip, nasopharynx, pharynx and oral cavity, esophagus, stomach, colon, rectum, liver, gall bladder, pancreas, larynx, lung and bronchus, melanoma of skin, breast, cervix, uterine, ovary, bladder, kidney, uterus, brain and other parts of the nervous system, thyroid, prostate, testes, Hodgkin's
 30 disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia.

In certain embodiments, the heterologous nucleotide sequence encodes a

biological response modifier such as a cytokine, cytokine receptor, hormone, growth factor or growth factor receptor. Non-limiting examples of such biological response modifiers include interferon (IFN)-alpha, IFN-beta, IFN gamma, interleukin (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-15, IL-18, IL-23, erythropoietin (EPO), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF), thymic stromal lymphopoietin (TSLP), TNFR and TNFR ligand superfamily members including TNFRSF 18 and TNFSF18. In other embodiments, the heterologous nucleotide sequence encodes an antibody. In yet other embodiments, the heterologous nucleotide sequence encodes a chimeric or fusion protein.

According to the invention, if the heterologous nucleotide sequence of the rAd vector is to be expressed in host cells, a transcriptional control element, also called a promoter/enhancer sequence, should be provided. The promoter/enhancer sequence may be widely active or may, alternatively, be tissue specific. The promoter/enhancer sequence may be derived from a non-adenovirus source or may be an adenovirus promoter. In a preferred embodiment, the promoter/enhancer sequences used to regulate the expression of the heterologous nucleotide sequence are not shared with those promoter/enhancer sequences that regulate the expression of the helper adenovirus nucleic acid sequences. In certain embodiments, the promoter is a constitutive promoter. In other embodiments, the promoter is an inducible promoter. In yet other embodiments, the promoter is a tissue-specific promoter. See Section 5.1, *supra*, for examples of promoters.

The desirable size of inserted non-adenovirus or heterologous nucleotide sequence is limited to that which permits packaging of the rAd vector into virions, and depends on the size of retained adenovirus sequences. The genome of a human adenovirus is approximately 36 kilobase pairs in length (measured to be 35938 nucleotides in length by Davison *et al.* (2003) J. Gen. Virology 84 (Pt 11), 2895-2908). The total size of the rAd to be packaged into virions should be about 37735 nucleotides in length (about 105% of the normal genome length).

Therefore, it may be desirable to exclude portions of the adenovirus genome in the

rAd vector in order to maximize expression of the inserted heterologous nucleotide sequence.

Insertion of a foreign gene sequence into a rAd vector of the invention can be accomplished by either a complete replacement of a viral coding region with a heterologous nucleotide sequence or by a partial replacement or by adding the heterologous nucleotide sequence to the viral genome. Complete replacement would probably best be accomplished through the use of PCR-directed mutagenesis. Briefly, PCR-primer A would contain, from the 5' to 3' end: a unique restriction enzyme site, such as a class IIS restriction enzyme site (i.e., a "shifter" enzyme; that recognizes a specific sequence but cleaves the DNA either upstream or downstream of that sequence); a stretch of nucleotides complementary to a region of the gene that is to be replaced; and a stretch of nucleotides complementary to the carboxy-terminus coding portion of the heterologous nucleotide sequence. PCR-primer B would contain from the 5' to 3' end: a unique restriction enzyme site; a stretch of nucleotides complementary to the gene that is to be replaced; and a stretch of nucleotides corresponding to the 5' coding portion of the heterologous or non-native gene. After a PCR reaction using these primers with a cloned copy of the heterologous or non-native gene, the product may be excised and cloned using the unique restriction sites. Digestion with the class IIS enzyme and transcription with the purified phage polymerase would generate a RNA molecule containing the exact untranslated ends of the viral gene that carries now a heterologous or non-native gene insertion. In an alternate embodiment, PCR-primed reactions could be used to prepare double-stranded DNA containing the bacteriophage promoter sequence, and the hybrid gene sequence so that RNA templates can be transcribed directly without cloning.

When inserting a heterologous nucleotide sequence into the rAd vector of the invention, the intergenic region between the end of the coding sequence of the heterologous nucleotide sequence and the start of the coding sequence of the downstream gene can be altered to achieve a desired effect. As used herein, the term "intergenic region" refers to nucleotide sequence between the stop signal of one gene and the start codon (*e.g.*, AUG) of the coding sequence of the next

downstream open reading frame. An intergenic region may comprise a non-coding region of a gene, *i.e.*, between the transcription start site and the start of the coding sequence (AUG) of the gene. This non-coding region occurs naturally in some viral genes.

5 The expression of the inserted heterologous nucleotide sequence can be determined by various indexes including, but not limited to, protein or mRNA expression levels, measured by following non-limiting examples of assays: immunostaining, immunoprecipitation and immunoblotting, enzyme-linked immunosorbent assay, nucleic acid detection (*e.g.*, Southern blot analysis, Northern blot analysis, Western blot analysis), employment of a reporter gene (*e.g.*, using a reporter gene, such as Green Fluorescence Protein (GFP) or enhanced Green Fluorescence Protein (eGFP), integrated to the viral genome the same fashion as the interested heterologous gene to observe the protein expression), or a combination thereof. Procedures of performing these assays are well known in the art (see, *e.g.*, Flint et al., PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, 10 PATHOGENESIS, AND CONTROL, 2000, ASM Press pp 25-26).

For example, expression levels can be determined by infecting cells in culture with a recombinant adenovirus of the invention and subsequently measuring the level of protein expression by, *e.g.*, Western blot analysis or ELISA using antibodies specific to the gene product of the heterologous nucleotide sequence, or measuring the level of RNA expression by, *e.g.*, Northern blot analysis using probes specific to the heterologous sequence. Similarly, expression levels of the heterologous sequence can be determined by infecting an animal model and measuring the level of protein expressed from the heterologous nucleotide sequence of the recombinant virus of the invention in the animal model. The protein level can be measured by obtaining a tissue sample from the infected animal and then subjecting the tissue sample to Western blot analysis or ELISA, using antibodies specific to the gene product of the heterologous sequence.

Further, if an animal model is used, the titer of antibodies produced by the animal against the gene product of the heterologous sequence can be determined by any

technique known to the skilled artisan, including but not limited to, ELISA.

According to the invention, a rAd vector may be propagated in microorganisms, for example, as part of a bacterial plasmid or bacteriophage, in order to obtain large quantities of rAd vector.

5

5.3 Generation of Cell Lines for Production of Recombinant Adenovirus

The present invention provides host cells comprising the helper adenovirus nucleic acid sequences described herein and methods for producing such cells. The host cells transfected or transformed with the helper adenovirus nucleic acid sequences are useful in the production of recombinant adenovirus, in particular replication-defective recombinant adenovirus. Specifically, the host cells of the present invention complement functions missing from the recombinant adenovirus vector and/or recombinant adenovirus of interest (*i.e.*, the adenoviral E1A, for example, SEQ ID NO: 17, and E1B, for example, SEQ ID NO: 18, coding regions). More specifically, host cells transfected or transformed with the helper adenovirus nucleic acid sequences described herein express adenoviral proteins that complement the recombinant adenovirus vectors described herein. Preferably, the host cells contain complementing adenoviral genes that lack any homology to those in the recombinant adenoviral vector of interest, which reduces the possibility of the viral genome recombining with the cellular DNA to produce replication competent adenovirus. Host cells that complement the recombinant adenovirus vectors described herein are sometimes referred to herein as "complementing cell lines", "rAd production cell lines", "rAd complementation cells" and "rAd complementation cell lines".

25

In a specific embodiment, the present invention provides an isolated host cell comprising: (a) first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein. In accordance with this embodiment, the second nucleic acid molecule, in certain

30

embodiments, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein. In a preferred embodiment, the present invention provides an isolated host cell comprising: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins. In accordance with these embodiments, the host cell may further comprise additional nucleic acid molecules comprising nucleotide sequences encoding an adenoviral E2a DNA binding protein, an adenoviral E2b pre-terminal protein, an adenoviral E2b IVa2 protein, adenoviral E4 proteins (*e.g.*, ORF 6, ORF 3 and ORF 6/7 of an adenoviral E4 gene), and/or an adenoviral protein encoded by L4 100K.

In certain embodiments, the present invention provides an isolated host cell comprising a nucleic acid molecule comprising: (i) a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (ii) a nucleotide sequence encoding an adenoviral E1B-55K protein. In certain other embodiments, the present invention provides an isolated host cell comprising a nucleic acid molecule comprising: (i) a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (ii) a nucleotide sequence encoding an adenoviral E2B polymerase; and (iii) a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins.

In a specific embodiment, the E1A proteins expressed by the host cells comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d/1101*) and amino acid residues 4-25 of an E1A 243R protein (*d/1101*); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d/1107*) of an E1A 289R protein and amino acid residues 111-123 (*d/1107*) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d/1108*) of an E1A 289R protein and amino acid residues 124-127

(*d*/1108) of an E1A 243R protein. In a preferred embodiment, the E1A proteins expressed by the host cells comprise: (a) a first deletion corresponding to amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); and (b) a second deletion corresponding to amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein.

The ability of the E1A adenoviral proteins to activate the early transcription units is required in all production cell lines for successful productive infection, but the ability of the E1A to induce the cell cycle may not be required in established cell lines that divide continuously. The mutated E1A adenovirus genes expressed in the rAd complementing cell lines of the present invention retain the ability to activate transcription, but are defective for induction of cellular DNA synthesis. The adenoviral E1A regions required for stimulation of cellular DNA synthesis, which are not expressed in the rAd complementing cell lines of the invention, may also be responsible for induction of apoptosis which may hinder successful establishment of rAd complementing cell lines.

Any type of cell may be used as a host cell. In a preferred embodiment, a cell that is permissible to adenovirus, preferably human adenovirus, infection is used. A host cell strain may be chosen which modulates, or modifies and processes the expression of a gene product in the specific fashion desired. Such modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells (*e.g.*, mammalian host cells) which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of a gene product may be used. Examples of such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT20 and T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin

chains), CRL7O3O and HsS78Bst cells. In a specific embodiment, the host cell is a A549, HCT-15, IGROV-1, HeLa, U87, W162 or 293-D22 cell. In a preferred embodiment, the host cell is a A549 cell. In certain embodiments, the host cells can be cultured and propagated in suspension.

5 In a preferred embodiment, human cells are used as host cells. Human established cell lines such as those from human tumor cells or human tumor cell lines have the ability to replicate indefinitely in culture. Human tumor cells, cells from human established cell lines or cells from human tumor cell lines are preferred over human primary cells for generating complementing cell lines of the present invention because the mutated E1A adenovirus genes expressed in the E1-
10 complementing cell lines of the present invention retain the ability to activate transcription, but are defective for induction of cellular DNA synthesis and for transformation of a primary cell line to a continuously replicating cell line or an established cell line. Such cell lines can be generated in accordance with standard
15 molecular biological techniques.

Host cells may be transiently or stably transfected with helper adenovirus nucleic acid sequences. Non-limiting methods for transfecting a host cell include the DEAE dextran method (McCutchen and Pagano, 1968, J. Natl. Cancer Inst. 41:351-357), the calcium phosphate procedure (Graham et al., 1973, J. Virol. 33:739-748), microinjection, lipofection, electroporation, and any other method
20 known in the art. Preferably, the helper adenovirus nucleic acid sequences are stably integrated into the nuclear genome of the host cells. It is believed that genomic integration of the heterologous nucleic acid sequences encoding the complementary factors is required to generate stable recombinant cell lines for adenoviral vector production. Additionally, complementation by transient
25 transfection is labor-intensive, difficult to scale-up and may provide low adenovirus yields. The introduction and stable integration of the heterologous nucleic acid sequences into the genome of the cell requires standard molecular biological techniques that are within the skill of the art, (see. *e.g.*, Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold
30 Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

For long-term, high-yield production of recombinant adenoviral proteins, stable expression is preferred. For example, cell lines which stably express the adenoviral proteins encoded by the helper adenovirus nucleic acid sequences may be engineered. Host cells can be transformed with nucleotide sequences controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign nucleotide sequences, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the adenoviral proteins encoded by the helper adenovirus nucleic acid sequences.

A number of selection systems may be used, including but not limited to, the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthineguanine phosphoribosyltransferase (Szybalska & Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:8-17) genes can be employed in tk-, hgprt- or aprt-cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62: 191-217; May, 1993, TIB TECH 11(5):155-2 15); and hygromycin (Santerre et al., 1984, Gene 30:147). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in

Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1.

The expression levels of adenoviral proteins encoded by helper adenovirus nucleic acid sequences can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an adenoviral protein(s) is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the adenoviral protein(s), production of the adenoviral protein(s) will also increase (Crouse et al., 1983, Mol. Cell. Biol. 3:257).

The present invention provides methods for producing a host cell for the production of replication-defective adenovirus comprising transforming or transfecting a cell (preferably, a human cell) with a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see above for examples of such adenoviral proteins), and the second nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E1B-55K protein (and preferably, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein). The cell may be transformed or transfected with the first and second nucleic acid molecules simultaneously or sequentially in any order. In a specific embodiment, the cell is transformed or transfected with the first nucleic acid molecule and then the second nucleic acid molecule.

The present invention provides methods for producing a cell for the production of replication-defective adenovirus comprising transforming or transfecting a cell (preferably, a human cell) with a first nucleic acid molecule, a

second nucleic acid molecule and a third nucleic acid molecule, wherein the first nucleic acid molecule comprises a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see above for examples of such adenoviral proteins), the second
5 nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E2b polymerase, and the third nucleic acid molecule comprises a nucleotide sequence encoding an adenoviral E1B-55K protein and preferably, a nucleotide sequence encoding an adenoviral E1B-55K protein and E1B-19K protein. The cell may be transformed or transfected with the first, second and third nucleic acid molecules
10 simultaneously or sequentially in any order. In a specific embodiment, the cell is transformed or transfected with the first nucleic acid molecule, the second nucleic acid molecule, and then the third nucleic acid molecule.

The rAd production cell lines of the invention may be propagated using standard cell culture techniques (see *e.g.*, R.I. Freshney, Culture of Animal Cells-A
15 Manual of Basic Techniques, Second Edition, Wiley-Liss, Inc. New York, N.Y., 1987). The rAd production cell lines are propagated by culturing the cells in an appropriate cell culture medium, such as Dulbecco's Modified Eagle's medium supplemented with 1-10% fetal bovine serum (in certain embodiments, it is 1% fetal bovine serum and other embodiments, it is 10% fetal bovine serum),
20 antibiotics (*e.g.*, 200 µg/ml hygromycin B and 200 µg/ml G418 for SL0003, and 150 µg/ml hygromycin B, 350 µg/ml G418, and 0.2 µg/ml puromycin for SL0006). For suspension culture of the rAd production cell lines, the rAd production cell lines are propagated by culturing the cells in, *e.g.*, OptiPro media supplemented with 0.1% pluronic F-68, 1% chemically purified lipids, 4 mM glutamax, and antibiotics (*e.g.*,
25 15 µg/ml hygromycin B, 35 µg/ml G418, and 0.02 µg/ml puromycin for SL0006). The antibiotics such as, *e.g.*, hygromycin B, G418 and puromycin are included in the cell culture medium to maintain the selection pressure on the cell line. In certain embodiments, the rAd production cell lines of the invention are propagated in suspension culture.

30 The cells may be cryopreserved and stored for future use. Preferably, the cells are cryopreserved by propagating the cells to late exponential phase of

growth; concentrating the cells; exchanging the growth medium to a medium supplemented with a cryoprotectant and a stabilizer; freezing the cells; and storing the cells at a temperature of 0°C or less. Preferably, the cells are stored at -70°C or less (*e.g.*, -80°C) or in liquid nitrogen or in the vapor phase of liquid nitrogen.

5 The cells may be concentrated by any method known in the art. For example, the cells may be concentrated by centrifugation, sedimentation, concentration with a perfusion device (*e.g.*, a sieve) or by filtration. Preferably, the cells are concentrated to at least about 1×10^7 cells/ml. The cells may be stored in any cryoprotectant known in the art. For example, the cryoprotectant may be dimethyl
10 sulfoxide (DMSO) or glycerol. The cells may be stored in any stabilizer known in the art. For example, the stabilizer may be methyl cellulose or serum.

Prior to freezing down, the concentrated cells may be portioned into several separate containers to create a cell bank. The cells may be stored, for example, in a glass or plastic vial or tube or in a cell culture bag. When the cells are needed
15 for future use, a portion of the cryopreserved cells (from one container) may be selected from the cell bank, thawed and propagated.

The rAd production cell line may be propagated or grown by any method known in the art for mammalian cell culture. Propagation may be done by a single step or a multiple step procedure. In a single step propagation procedure, the
20 production cells are removed from storage and inoculated directly to a culture vessel where production of virus is going to take place. In a multiple step propagation procedure, the production cells are removed from storage and propagated through a number of culture vessels of gradually increasing size until reaching the final culture vessel where the production of recombinant adenovirus is
25 going to take place. During the propagation steps, the cells are grown under conditions that are optimized for growth. Culture conditions, such as temperature, pH, dissolved oxygen level and the like are those known to be optimal for the particular cell line and will be apparent to the skilled person or artisan within this field (see *e.g.*, Animal Cell culture: A Practical Approach 2nd edition, Rickwood, D.
30 and Hames, B.D. eds., Oxford University Press, New York (1992)).

The rAd production cells or rAd production cell lines may be grown in any suitable vessel which is known in the art. For example, cells may be grown and the infected cells may be cultured in a biogenerator or a bioreactor. Generally, "biogenerator" or "bioreactor" means a culture tank, generally made of stainless steel or glass, with a volume of 0.5 liter or greater, comprising an agitation system, a device for injecting a stream of CO₂ gas and an oxygenation device. Typically, it is equipped with probes measuring the internal parameters of the biogenerator, such as the pH, the dissolved oxygen, the temperature, the tank pressure or certain physicochemical parameters of the culture (for instance the consumption of glucose or of glutamine or the production of lactate and ammonium ions). The pH, oxygen, and temperature probes are connected to a bioprocessor which permanently regulates these parameters. In other embodiments, the vessel is a spinner flask, a roller bottle, a shaker flask or in a flask with a stir bar providing mechanical agitation. In another embodiment, the vessel is a WAVE Bioreactor (WAVE Biotech, Bridgewater, NJ, U.S.A.).

Cell density in the culture may be determined by any method known in the art. For example, cell density may be determined microscopically (*e.g.*, hemacytometer) or by an electronic cell counting device (*e.g.*, COULTER COUNTER; AccuSizer 780/SPOS Single Particle Optical Sizer).

5.3.1 SL0003 Cell Line

As described in Example 1, the transformed cell line A549E1Ad/01/07, that constitutively expressed the E1A mutated E1Ad/01/07 gene, was selected for further development because it supported replication of E1-deleted rAd vectors at levels higher than A549 cell clones expressing either wild-type E1A or the single mutations E1Ad/1101 or E1Ad/1107. As shown in Example 1, *infra*, A549 cell clones, A549E1Ad/01/07-1 to A549E1Ad/01/07-5, supported replication of E1-deleted rAd vectors at levels higher than A549 cell clones A549E1Awt-1 to A549E1Awt-5, or A549 cell clones A549E1Ad/1101-1 to A549E1Ad/1101-5, or A549 cell clones A549E1Ad/1107-1 to A549E1Ad/1107-5.

The transformed cell line, A549E1Ad/01/07, was also selected for further development because of its reduced sensitivity to apoptosis during adenovirus vector production. A549 clones expressing wild-type E1A, *i.e.*, A549E1A*wt*, were especially sensitive to apoptosis following infection with E1-deleted rAd vectors and viral yields were extremely low. The rapid induction of apoptosis in clone A549E1A*wt*-2 suggested that early events in viral infection may supply death signals that may be recognized by A549 cells expressing wild-type E1A but not E1Ad/01/07.

Apoptosis in adenovirus-infected cells has been reported to be stimulated though p53-dependent and p53-independent pathways (Teodoro *et al.*, (1995) Oncogene 11:467-474). It was found that both E2F and p53 pathways were stimulated in the A549*wt*-2 clone as compared to the A549E1Ad/01/07 clones in which E2F and p53 transcriptional activity was similar to the parental A549 cells. It was found that A549E1A*wt*-2 cells were driven into apoptosis by low levels of cycloheximide, but that A549E1Ad/01/07 clones were unaffected by this treatment. The stimulation of the E2F and p53 pathways by wild-type E1A was not sufficient to induce apoptosis in the A549*wt*-2 clone, but may have contributed to the increased sensitivity of these cells to death stimuli.

Although the transformed cell line, A549E1Ad/01/07, was capable of producing replication defective adenovirus, it was reasoned that the viral yield may be further improved by complementation using E1B. It was unknown whether both E1B genes were needed for rAd vector complementation in the E1Ad/01/07-expressing A549 cell line. Analysis of virus yield using a series of E1B-mutant viruses showed that in A549E1Ad/01/07-4 cells, expression of E1B-55K alone was sufficient for production of the mutant viruses at wild-type levels. These results suggested that efficient complementation may be achieved in A549 cells by E1Ad/01/07 plus E1B55K, which was subsequently achieved in the SL0003 cell line. The yield of rAd vectors from the SL0003 cell line was similar to that obtained from 293 cells, without generation of detectable replication competent adenovirus (RCA).

The SL0003 cell line was deposited under the Budapest Treaty, on September 22, 2004 with the American Type Culture Collection (ATCC), 10801

University Blvd., Manassas, VA, 20110-2209, USA, under the indicated name and accession number as follows; Deposit name: "SL0003"; ATCC Accession Number: PTA-6231. All restrictions on access to the cell line deposited with the ATCC will be removed upon grant of a patent.

5

5.3.2 SL0006 Cell Line

As described in Example 2, to improve viral yield, the transformed cell line, A549E1Ad/01/07, was transformed with a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E2b polymerase and a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins. The results presented in Example 2 demonstrate that efficient complementation may be achieved in A549 cells by E1Ad/01/07 plus E2b polymerase, E1B-55K and E1B-19K. The yield of rAd vectors from the SL0006 cell line was similar to that obtained from 293 cells, without generation of detectable replication competent adenovirus (RCA).

10

The SL0006 cell line was deposited under the Budapest Treaty, on April 7, 2005 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110-2209, USA, under the indicated name and accession number as follows; Deposit name: "SL0006"; ATCC Accession Number: PTA-6663. All restrictions on access to the cell line deposited with the ATCC will be removed upon grant of a patent.

15

5.4 Production of Recombinant Adenovirus

In accordance with the invention, recombinant adenovirus (preferably, recombinant replication-defective adenovirus) may be produced by co-transfecting an appropriate cell type with rAd vector and helper adenovirus nucleic acid sequences. Co-transfection may be performed by the DEAE dextran method (McCutchen and Pagano, 1968, J. Natl. Cancer Inst. 41:351-357), the calcium phosphate procedure (Graham et al., 1973, J. Virol. 33:739-748) or by any other method known in the art, including but not limited to microinjection, lipofection, and electroporation. Amounts of rAd vector and helper adenovirus nucleic acid

20

25

30

sequences used in transfection are approximately 0.2 to 10 μg of DNA per 10^6 cells, but may vary among different DNA constructs and cell types. Cells suitable for transfection include any cell line permissive for adenovirus infection, including, but not limited to HeLa cells, 293-D22 cells, A549 cells, HCT-15 cells, IGROV-1 cells, U87 cells and W162 cells.

Alternatively, a rAd complementing cell line may be transfected with rAd vector to produce of recombinant adenovirus (preferably, recombinant replication-defective adenovirus). In a specific embodiment, the present invention provides a method for producing recombinant adenovirus comprising culturing a rAd complementing cell line transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); and (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein (and preferably, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein). In a preferred embodiment, the present invention provides a method for producing recombinant adenovirus comprising culturing a rAd complementing cell line transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein, and preferably, an adenoviral E1B-19K protein.

In a specific embodiment, the present invention provides a method for propagating recombinant adenovirus comprising culturing a rAd complementing cell line infected with a recombinant adenovirus (preferably, a replication-defective

adenovirus) under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); and (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein (and preferably, does not comprise a nucleotide sequence encoding an adenoviral E1B-19K protein). In a preferred embodiment, the present invention provides a method for propagating recombinant adenovirus comprising culturing a rAd complementing cell line infected with a recombinant adenovirus (preferably, a replication-defective adenovirus) under conditions so as to permit replication of the viral genome in the cell line, wherein the cell line comprises: (a) a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members (see the description above regarding such E1A proteins); (b) a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein, and preferably, an adenoviral E1B-19K protein.

Recombinant adenovirus of the present invention may be produced by any suitable method, many of which are known in the art (see, *e.g.*, Berkner et al., Nucl. Acids Res. 12:925-941 (1984); Berkner et al. Nucl. Acids. Res. 11:6003-6020 (1983); Brough *et al.*, Virol. 190:624-634 (1992)). In the preferred practice of the invention, the recombinant adenoviruses are derived from the human adenoviridae. In a preferred embodiment of the invention, the recombinant adenovirus is derived from the human adenovirus serotype 2 or 5. In another preferred practice of the invention, the recombinant adenovirus is a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, complete) deletion of E1A coding region (*e.g.*, SEQ ID NO: 17) and E1B coding region (*e.g.*, SEQ ID NO: 18), and may include one or more additional heterologous genes. In another preferred practice of the invention, the recombinant adenovirus is a replication-defective adenovirus and comprises a mutated genome with a partial or

complete (preferably, complete) deletion of the E1A coding region (*e.g.*, SEQ ID NO: 17), E1B coding region (*e.g.*, SEQ ID NO: 18), and E2B polymerase coding region (for example, SEQ ID NO: 23), and includes one or more heterologous nucleotide sequences. In a more preferred practice of the invention, the recombinant adenovirus is a replication-defective adenovirus and comprises a mutated genome with a partial or complete (preferably, complete) deletion of the E1A coding region, E1B coding region, E2b polymerase coding region, and E3 coding region, and includes one or more heterologous nucleotide sequences in the deleted E3 coding region. The preferred recombinant adenoviruses of the present invention comprise viral DNA sequences that lack any homology with the adenoviral DNA sequences in the rAd production cell, which reduces the possibility of the viral genome recombining with the cellular DNA to produce RCAs.

In certain embodiments, the quantity of recombinant adenovirus is titrated. Titrating the quantity of the adenovirus in the culture may be performed by techniques known in the art. In a particular embodiment, the concentration of viral particles is determined by the Resource Q assay as described by Shabram, *et al.* Human Gene Therapy 8:453-465 (1997). As used herein, the term "lysis" refers to the rupture of the virus-containing cells. Lysis may be achieved by a variety of means well known in the art. For example, mammalian cells may be lysed under low pressure (100-200 psi differential pressure) conditions, by homogenization, by microfluidization, or by conventional freeze-thaw methods. Exogenous free DNA/RNA may be removed by degradation with DNase/RNase.

Virus-containing cells may be frozen. Virus may be harvested from the virus-containing cells and the medium. In one embodiment, the virus is harvested from both the virus-containing cells and the medium simultaneously. In a particular embodiment, the virus producing cells and medium are subjected to cross-flow microfiltration, for example, as described in U.S. Patent Number 6,146,891, under conditions to both simultaneously lyse virus-containing cells and clarify the medium of cell debris which would otherwise interfere with virus purification.

As used herein, the term "harvesting" means the collection of the cells containing the recombinant adenovirus from the media and may include collection of the recombinant adenovirus from the media. This may be achieved by conventional methods such as differential centrifugation or chromatographic means. At this stage, the harvested cells may be stored or further processed by lysis and purification to isolate the recombinant virus. For storage, the harvested cells should be buffered at or about physiological pH and frozen at -70°C.

Virus may also be harvested from the virus-containing cells and medium separately. The virus-containing cells may be collected separately from the medium by conventional methods such as differential centrifugation. Harvested cells may be stored frozen or further processed by lysis to liberate the virus. Virus may be harvested from the medium by chromatographic means. Exonuclease free DNA/RNA may be removed by degradation with DNase/RNase, such as BENZONASE (American International Chemicals, Inc.).

The virus harvest may be further processed to concentrate the virus by methods such as ultrafiltration or tangential flow filtration, for example, as described in U.S. Patent Numbers 6,146,891; 6,544,769 and 6,783,983.

As used herein, the term "recovering" means the isolation of a substantially pure population of recombinant virus particles from the lysed producer cells and optionally from the supernatant medium. Viral particles produced in the cell cultures of the present invention may be isolated and purified by any method which is commonly known in the art. Conventional purification techniques such as chromatographic or differential density gradient centrifugation methods may be employed. For example, the viral particles may be purified by cesium chloride gradient purification, column or batch chromatography, diethylaminoethyl (DEAE) chromatography (Haruna *et al.* Virology 13: 264-267 (1961); Klemperer *et al.*, Virology 9: 536-545 (1959); Philipson Virology 10: 459-465 (1960)), hydroxyapatite chromatography (U.S. Patent Application Publication Number US2002/0064860) and chromatography using other resins such as homogeneous cross-linked polysaccharides, which include soft gels (*e.g.*, agarose), macroporous polymers based on synthetic polymers, which include perfusion chromatography resins with

large "throughpores", "tentacular" sorbents, which have tentacles that were designed for faster interactions with proteins (*e.g.*, fractogel) and materials based on a soft gel in a rigid shell, which exploit the high capacity of soft gels and the rigidity of composite materials (*e.g.*, Ceramic HyperD® F) (Boschetti, Chromatogr. 5 658: 207 (1994); Rodriguez, J. Chromatogr. 699: 47-61 (1997)). In the preferred practice of the invention, the virus is purified by column chromatography in substantial accordance with the process of Huyghe, *et al.* (1995) Human Gene Therapy 6: 1403-1416 as described in Shabram, *et al.*, United States Patent 5,837,520 issued November 17.

10 The rAd production cell lines producing virus may be cultured in any suitable vessel which is known in the art. For example, cells may be grown and the infected cells may be cultured in a biogenerator or a bioreactor. Generally, "biogenerator" or "bioreactor" means a culture tank, generally made of stainless 15 steel or glass, with a volume of 0.5 liter or greater, comprising an agitation system, a device for injecting a stream of CO₂ gas and an oxygenation device. Typically, it is equipped with probes measuring the internal parameters of the biogenerator, such as the pH, the dissolved oxygen, the temperature, the tank pressure or certain physicochemical parameters of the culture (for instance the consumption of 20 glucose or of glutamine or the production of lactate and ammonium ions). The pH, oxygen, and temperature probes are connected to a bioprocessor which permanently regulates these parameters. In other embodiments, the vessel is a spinner flask, a roller bottle, a shaker flask or in a flask with a stir bar providing mechanical agitation. In another embodiment, a the vessel is a WAVE Bioreactor 25 (WAVE Biotech, Bridgewater, NJ, U.S.A.).

Recombinant adenoviruses may be propagated in the rAd production cell lines of the invention. Virus may be produced by culturing the cells; optionally adding fresh growth medium to the cells; inoculating the cells with the virus; incubating the inoculated cells; optionally adding fresh growth medium to the 30 inoculated cells; and optionally harvesting the virus from the cells and the medium. Typically, when the concentration of viral particles, as determined by conventional

methods, such as high performance liquid chromatography using a Resource Q column, as described in Shabram, *et al.* Human Gene Therapy 8:453-465 (1997), begins to plateau, the harvest is performed.

Proteins produced by recombinant adenoviruses grown in the rAd production cell lines of the invention (*e.g.*, adenovirus comprising a deletion of the E1A and E1B coding regions and comprising a heterologous nucleotide sequence, or adenovirus comprising a deletion of E1A, E1B and E2B polymerase coding regions and comprising a heterologous nucleotide sequence) may also be isolated and purified. Proteins, polypeptides and peptides may be purified by standard methods, including, but not limited to, salt or alcohol precipitation, affinity, preparative disc-gel electrophoresis, isoelectric focusing, high pressure liquid chromatography (HPLC), reversed-phase HPLC, gel filtration, cation and anion exchange and partition chromatography, and countercurrent distribution. Such purification methods are well known in the art and are disclosed, *e.g.*, in "*Guide to Protein Purification*", Methods in Enzymology, Vol. 182, M. Deutscher, Ed., 1990, Academic Press, New York, NY.

5.5 Utility of Recombinant Adenovirus

The recombinant adenoviruses of the invention can be used *in vitro* to express proteins, polypeptides and peptides of interest. The recombinant adenoviruses of the invention can also be used in gene therapy. For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIBTECH 11(5):155-215.

The recombinant adenoviruses can be used for *in vivo* or *ex vivo* gene therapy. For *in vivo* gene therapy, recombinant adenovirus is directly administered to a subject. For *ex vivo* gene therapy, cells are infected with the recombinant adenovirus *in vitro* and then the infected cells are transplanted into the subject. In

a specific embodiment, the recombinant adenovirus is directly administered *in vivo*, where a protein of interest is expressed.

In another embodiment, a cell is infected with a recombinant adenovirus and the resulting recombinant cell is administered to a subject. The resulting recombinant cells can be delivered to a subject by various methods known in the art. Recombinant blood cells (*e.g.*, hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art. In accordance with the invention, any cells which can be infected with a recombinant adenovirus can be for purposes of gene therapy. Non-limiting examples include epithelial cells (*e.g.*, respiratory epithelial cells), endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes, blood cells (such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes), and various stem or progenitor cells (in particular, hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.). In a preferred embodiment, the cell used for gene therapy is autologous to the subject. In an embodiment in which recombinant cells are used in gene therapy, the proteins encoded by the genome of the recombinant adenovirus are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect.

The recombinant adenovirus of the present invention may be used to immunize a subject. For example, the recombinant adenovirus may be used to generate antibodies against a heterologous antigen expressed by the recombinant adenovirus. The amount of recombinant adenovirus to be used to immunize a subject and the immunization schedule will be determined by a physician skilled in the art and will be administered by reference to the immune response and antibody titers of the subject.

The antibodies generated against an antigen by immunization with a recombinant adenovirus may be used in diagnostic immunoassays, passive immunotherapy, and generation of anti-idiotypic antibodies. The generated

antibodies may be isolated by standard techniques known in the art (*e.g.*, immunoaffinity chromatography, centrifugation, precipitation, etc.) and used in diagnostic immunoassays. The antibodies may also be used to monitor treatment and/or disease progression. Any immunoassay system known in the art may be used for this purpose including, but not limited to, competitive and noncompetitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assays), "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assays, to name but a few.

The recombinant of the present invention can be used to produce antibodies for use in passive immunotherapy, in which short-term protection of a subject is achieved by the administration of pre-formed antibody directed against a heterologous antigen. The antibodies generated by the recombinant adenovirus of the present invention can also be used in the production of anti-idiotypic antibody. The anti-idiotypic antibody can then in turn be used for immunization, in order to produce a subpopulation of antibodies that bind the initial antigen (Jerne, 1974, *Ann. Immunol. (Paris)* 125c:373; Jerne et al., 1982, *EMBO J.* 1:234).

In certain embodiments, the antibody produced by immunization with a recombinant adenovirus is modified prior to administration to a subject. For example, the antibody may be humanized and/or affinity matured.

5.6 Compositions and Methods of

Administering Recombinant Adenovirus

The invention encompasses compositions comprising a recombinant adenovirus (preferably, replication-defective recombinant adenovirus) generated by the methods of the invention. In a preferred embodiment, the compositions are pharmaceutical compositions suitable for administration to a subject.

The pharmaceutical compositions of the present invention comprise an effective amount of recombinant adenovirus, and a pharmaceutically acceptable

carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeiae for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. These compositions can be formulated as a suppository. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain an effective amount of recombinant adenovirus, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Methods of administration of the compositions include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The pharmaceutical compositions of the present invention may be administered by any convenient route, for example by
5 infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary
10 administration can be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation,
15 local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site
20 (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

In another embodiment, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another
25 embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger & Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al.,
30 1989, Ann. Neurol. 25:351 (1989); Howard et al., 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed in proximity of

the composition's target, *i.e.*, the lung, thus requiring only a fraction of the systemic dose (see, *e.g.*, Goodson, 1984, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533).

5 In a specific embodiment, a composition of the invention is a vaccine or immunizing composition comprising a recombinant adenovirus (preferably, replication-defective recombinant adenovirus) generated by the methods of the invention, and a suitable excipient. Many methods may be used to introduce the vaccine compositions, these include but are not limited to intranasal, intratracheal,
10 oral, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes. It may be preferable to introduce the recombinant adenovirus vaccine composition via the natural route of infection of adenovirus.

5.7 Plasmid Systems

15 The present invention provides plasmid systems for generating cell lines for production of recombinant adenovirus. In a specific embodiment, the present invention provides a plasmid system for generating a cell line (preferably, a human cell line) for the production of recombinant adenovirus comprising in separate containers: (a) a first expression cassette comprising a regulatory element operably
20 linked to a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; and (b) a second expression cassette comprising a regulatory element in said cell line operably linked to a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K
25 protein. In an alternative embodiment, the plasmid system comprises a single expression cassette that comprises a nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members and a nucleotide sequence encoding an adenoviral E1B-55K protein.

30 In a specific embodiment, the present invention provides a plasmid system for generating a cell line (preferably, a human cell line) for the production of

recombinant adenovirus comprising in separate containers: (a) a first expression cassette comprising a regulatory element operably linked to a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (b) a second expression cassette comprising a regulatory element operably linked to a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third expression cassette comprising a regulatory element operably linked to a third nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein. In an alternative embodiment, the plasmid system comprises a single expression cassette that comprises a nucleic acid molecule comprising (i) a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, (ii) a nucleotide sequence encoding an adenoviral E1B-55K protein and (iii) a nucleotide sequence encoding an adenoviral E2B polymerase.

In another embodiment, the present invention provides a plasmid system for generating a cell line (preferably, a human cell line) for the production of recombinant adenovirus comprising in separate containers: (a) a first expression cassette comprising a regulatory element operably linked to a first nucleic acid molecule comprising a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members; (b) a second expression cassette comprising a regulatory element operably linked to a second nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E2B polymerase; and (c) a third expression cassette comprising a regulatory element operably linked to a third nucleic acid molecule comprising a nucleotide sequence encoding an adenoviral E1B-55K protein and an adenoviral E1B-19K protein. In an alternative embodiment, the plasmid system comprises a single expression cassette that comprises a nucleic acid molecule comprising (i) a nucleotide sequence encoding adenoviral E1A proteins deficient in binding to p300 protein family members and pRb protein family members, (ii) a

nucleotide sequence encoding adenoviral E1B-55K and E1B-19K proteins and (iii) a nucleotide sequence encoding an adenoviral E2B polymerase

In a specific embodiment, the E1A proteins encoded by the first expression cassette comprise: (a) a first deletion corresponding to: (i) amino acid residues 4-25 of an E1A 289R protein (*d*/1101) and amino acid residues 4-25 of an E1A 243R protein (*d*/1101); or (ii) amino acid residues 36-49 of an E1A 289R protein and amino acid residues 36-49 of an E1A 243R protein; and (b) a second deletion corresponding to: (i) amino acid residues 111-123 (*d*/1107) of an E1A 289R protein and amino acid residues 111-123 (*d*/1107) of an E1A 243R protein; or (ii) amino acid residues 124-127 (*d*/1108) of an E1A 289R protein and amino acid residues 124-127 (*d*/1108) of an E1A 243R protein.

6. EXAMPLES

The following examples are merely illustrative and not meant to be limiting of the scope of the invention described herein.

Example 1: Generation an E1A and E1b Complementing Cell Line and Use of the Cell Line in the Production of Recombinant Adenovirus

This example demonstrates the utility of an E1A and E1b complementing cell line for the production of high titers of replication-defective, helper-independent recombinant viruses.

I. Materials & Methods

Cell Culture

293 (ATCC# CRL-1573), A549 (ATCC# CCL-185) and HeLa (ATCC# CCL-2) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (JRH Biosciences, Lenexa, KS), 1% (v/v) antibiotic-antimycotic solution (Cellgro, Kansas, MO) and 1 mM sodium pyruvate (BioWhittaker, Inc., Walkersville, MD).

Plasmids

The Ad5 wild-type E1A gene, and E1A sequences containing the E1A Δ 1101, E1A Δ 1107 and E1A Δ 01/07 mutations were cloned by standard procedures from pXC1 (McKinnon *et al.*, (1982) Gene 19:33-42) or Ad- Δ 01/07 (Howe *et al.*, (1990) Proc. Natl. Acad. Sci. USA 87:5883-5887) into the RSV promoter/SV40 polyA expression cassette of pRc/RSV-Neo (Invitrogen, Carlsbad CA) to create pRc/RSV-E1A Δ wt, pRc/RSV-E1A Δ 1101, pRc/RSV-E1A Δ 1107 and pRc/RSV-E1A Δ 01/07. pcDNA3.1-E1B-55K, was constructed by cloning the E1B-55K gene from pXC1 using PCR into the CMV promoter/BGH poly A expression cassette of pcDNA3.1-hygro (Invitrogen Carlsbad, CA). p53con-luc contained 4 consensus p53 binding sites, and a TATA box from the simian virus-40 (SV40) early promoter (Ramachandra *et al.*, (2001) Nat. Biotechnol. 19: 1035-1041), upstream of the luciferase gene in pGL3-basic (Promega, Madison, WI). pE2F-luc contained 4 copies of the E2F binding sites from the adenovirus early region 2 promoter and an SV40 TATA box upstream of the luciferase gene in pGL3-basic.

Viral Constructs

rAd- β -gal and rAd-GFP were E1/E3 deleted adenovirus vectors with expression cassettes inserted into the E1-deletion and which contained either the β -galactosidase (β -gal) gene, or green fluorescent protein (GFP) gene, under control of the constitutively active CMV immediate early promoter (Cheney *et al.*, (1998) Cancer Res. 58:2331-2334; Wills *et al.*, (1994) Hum. Gene Ther. 5:1079-1088). The p53 reporter rAd-PRE-GFP contained an expression cassette in the E3-deletion in which a p53-response element (Ramachandra *et al.*, (2001) Nat. Biotechnol. 19:1035-1041) regulated expression of GFP. Ad5- Δ 309 (Jones and Shenk, (1979) Proc. Natl. Acad. Sci. 76:3665-3669) was used as a wild-type control virus. The Ad5- Δ 309 based mutant viruses E1B/19K-, which does not produce the E1B-19K protein (Marcellus *et al.*, (1996) J. Virol. 70:6207-6215), and NT1010, which has a large deletion in the E1A region (Whyte *et al.*, (1989) Cell 56:67-75), have been described previously. Δ 1520 (Barker and Berk, (1987) Virology 156:107-121) was a chimeric adenovirus (Ad2 and Ad5- Δ 309) containing a deletion in the E1B coding region (Ad5 coordinates 2496 – 3233) and a stop codon at the third codon of E1B-

55K. The Ad-E1B⁻ virus was constructed by removing the E1B coding region in plasmid pXC1 by *EcoM* and *Bgl*II digestion, Klenow fill in and blunt end ligation to create pXC1-E1B⁻. Ad sequence containing the mutated E1B region was transferred from pXC1-E1B⁻ into a larger transfer plasmid pTG9530 (Transgene S.A., Strasbourg), to create pTG9530-E1B⁻. Homologous recombination in *E. coli* strain BJ5183 (Chartier *et al.*, (1996) J. Virol. 70:4805-4810) was used to generate infectious Ad-E1B⁻ adenoviral DNA by transformation of pTG9530-E1B⁻ and viral plasmid pTG4213-Ad5-*d*/309. The resulting Ad-E1B⁻ plasmid was isolated and transfected into 293 cells to generate virus. All viruses were purified by column chromatography using a method described previously (Huyghe *et al.*, (1995) Hum. Gene Ther. 6:1403-1416). Particle concentrations were estimated by an ion exchange HPLC-based method (RQ-HPLC) that determines concentrations of intact adenovirus particles relative to an internal adenovirus standard (Shabram *et al.*, (1997) Hum. Gene Ther. 8:453-465).

Selection of A549 cell clones expressing E1A^{wt}, E1A-mutant proteins and E1B-55K

For selection of clones expressing E1A^{wt} or E1A-mutant proteins plasmids pRc/RSV-E1A^{wt}, pRc/RSV-E1A1101, pRc/RSV-E1A1107 and pRc/RSV-E1A01/07TM were transfected into A549 cells using SuperfectTM reagent (Qiagen, Valencia CA). After incubation for two days, selection was initiated in growth medium containing 350 µg/ml neomycin (Invitrogen, Carlsbad, CA). Drug-resistant colonies from the cultures transfected with the E1A^{wt} or E1A-mutant selection plasmids, were trypsinized, established as cell pools, and dilution cloned in 96-well plates. Selection in culture medium containing neomycin was carried out three more weeks, after which 48 individual clones from each transfection were expanded and screened for virus production potential. A549-E1A^d/01/07-4 based cell lines were engineered to express E1B-55K using the same procedure except that A549-E1A^d/01/07-4 cells were transfected with pcDNA3.1-E1B-55K and selected in 350 µg/ml hygromycin (Invivogen, San Diego, CA)

Generation of the E1-complementing cell line

The Ad5 E1A sequences containing the E1A Δ 01/07 mutation were cloned by standard procedures from Ad- Δ 01/07 (Howe *et al.*, (1990) Proc. Natl. Acad. Sci. USA 87:5883-5887) into the RSV promoter/SV40 polyA expression cassette of pRc/RSV-E1A to create pRc/RSV-E1A Δ 01/07. See Figure 2 for a map of pRc/RSV-E1A Δ 01/07. pcDNA3.1-E1B-55K was constructed by cloning the E1B-55K gene from pXC1 (McKinnon *et al.*, (1982) Gene 19:33-42) using PCR into the CMV promoter/BGH poly A expression cassette of pcDNA3.1-hygro (Invitrogen Carlsbad, CA). See Figure 3 for a map of pcDNA3.1-E1B-55K.

The plasmid pRc/RSV-E1A01/07 was transfected into A549 cells using Superfect reagent (Qiagen, Valencia CA). After incubation for two days, selection was initiated in growth medium containing 350 μ g/ml neomycin (Invitrogen, Carlsbad, CA). Drug-resistant colonies from the transfected cultures were trypsinized, established as cell pools, and dilution cloned in 96-well plates. Selection in culture medium containing neomycin was carried out three more weeks, after which 48 individual clones from the transfection were expanded and screened for virus production potential. The plasmid pcDNA3.1-E1B-55K was transfected into A549-E1A Δ 01/07-4, a transformed cell line, using Superfect reagent. After incubation for two days, selection was initiated in growth medium containing hygromycin (350 μ g/ml) (Invivogen, San Diego, Ca). Drug-resistant colonies from the transfected cultures were trypsinized, established as cell pools, and dilution cloned in 96-well plates. Selection in culture medium, Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (JRH Biosciences, Lenexa, KS), hygromycin (200 μ g/ml) and neomycin (200 μ g/ml), was carried out three more weeks, after which 48 individual clones from the transfection were expanded and screened for virus production potential.

Screening procedures for cells clones

The virus production potential of A549-based clones expressing E1A Δ wt or E1A-mutant proteins was assessed by infecting cells that were plated on 6-well

plates with rAd-GFP (1×10^8 particles/ml). Virus replication efficiency was estimated by monitoring green fluorescence protein intensity and cytopathic effect (CPE). For screening E1A01/07-4 based clones established by transfection with pcDNA3.1-E1B-55K cells were infected with rAd-PRE-GFP (1×10^8 particles/ml) and clones with low GFP intensity, suggesting reduced p53 activity, and robust CPE were chosen for further characterization.

Virus production in the selected clones was determined by measuring the number of particles produced on a per cell basis. For this assay, cells were infected with rAd vector at 5×10^8 particles/ml, and at the time of infection cells in duplicate plates or flasks were trypsinized and counted using a Coulter Counter (Beckman-Coulter, Miami, FL). At a time point when the infection was complete (3-4 days) cells, and media were collected, freeze/thawed three times and centrifuged to remove cellular debris. The particle concentration in the cleared lysates was determined using anion-exchange high-performance liquid chromatography (Shabram *et al.*, (1997) Hum. Gene Ther. 453-465).

Western blotting analysis to determine E1A protein levels

Whole cell protein lysates were prepared by incubation of the indicated cells in lysis A buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 0.5% [vol/vol] IGEPAL CA-630 [Sigma, St. Louis, MO] and protease-inhibitor cocktail [Roche, Indianapolis, IN]) followed by centrifugation. Total protein concentration in the lysates was determined by the Bio-Rad protein assay (Bio-Rad, Hercules, CA) and 50 μ g aliquots were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with gradient (4% -12%) NUPAGE gels (Invitrogen, Carlsbad, CA). After transfer onto PVDF membranes (Invitrogen, Carlsbad, CA) western detection was performed using antibodies specific for E1A (M73, Calbiochem, La Jolla, CA) or α -actin (Sigma-Aldrich, St. Louis, MO). Binding patterns were determined by incubating the membranes with horseradish peroxidase-conjugated anti-mouse immunoglobulin G and M (Roche, Indianapolis, IN) and detected by enhanced chemiluminescence (Amersham BioSciences, Piscataway, NJ).

Analysis of viral DNA

Small molecular weight DNA was isolated from cells infected with rAd- β -gal (1 x 10⁸ particles/ml) on 6-well plates at the indicated time points using a modified Hirt extraction (Hirt, 1967). Infected cells were harvested by scraping and lysed in TNE buffer [500mM NaCl, 10 mM Tris (7.5), 10mM EDTA, 1% SDS, 0.5 mg/ml proteinase K (Sigma), 0.25 mg/ml pronase E (Sigma)]. After a freeze-thaw cycle lysates were cleared by centrifugation, extracted with a phenol:chloroform mixture (Sigma, St. Louis, MI) and ethanol precipitated. The nucleic acid pellets were suspended in 60 μ l of TE containing RNase (Ambion, Austin, TX), after which 12 μ l samples were restricted with *Xho*I, separated on 1% agarose gels. DNA restriction patterns were visualized by ethidium bromide staining.

Flow cytometric determination of apoptosis with FITC-VAD-FMK

E1A^{wt}, E1A-mutant clones and A549 control cells were plated on 6-well plates at 150,000 cells per well and infected at 24 hours with rAd- β -gal (1 x 10⁸ particles/ml). At 20 hours after infection, 5 μ M CaspACE FITCTM-VAD-FMK (Promega, Madison, WI) was added directly to the culture medium. After incubation for 20 minutes at 20°C, the cells were trypsinized, washed two times with PBS and fixed in 0.5% formaldehyde for 30 minutes at 20°C. Flow cytometry analysis was performed using an FACSCaliburTM (Becton Dickinson, San Jose, CA) and fluorescence was measured at 530 nm (excitation of 488 nm).

Luciferase Assays

Lysates of cells transfected with reporter plasmids using Superfect (Qiagen, Valencia, CA) were mixed with the reconstituted luciferase substrate (Promega, Madison, WI) according to the manufactures specifications. Luciferase activity of

each lysate was determined using an Analyst AD (Molecular Devices, Sunnyvale, CA).

Immunoprecipitation of E1B-55K

5 Protein lysates (1 mg total protein), prepared as described above, were pre-cleared with protein-G sepharoseTM beads (Amersham BioSciences, Piscataway, NJ) and incubated with 5 µg of the E1B-55K specific mouse monoclonal antibody, 2A6 (Sarnow *et al.*, (1982) Cell 28:387-394). E1B-55K-immunoglobulin complexes were purified on protein-G sepharose, washed extensively with lysis buffer and incubated
10 with SDS-PAGE sample buffer containing reducing agent (Invitrogen, Carlsbad, CA). The samples were separated on SDS-PAGE gels and E1B-55K protein was detected by Western blot as described above, using the 2A6 monoclonal antibody.

Serial Passage of an E1-Deleted rAd-vector in 293 or SL0003

The rAd-β-gal virus to be used for serial passage was first plaque purified
15 three times, propagated using SL0003 cells grown in a cell factory (Nunc A/S, Kamstrupvej, Denmark) and purified by column chromatography. The resulting virus stock, rAd-β-gal (p0), tested free of replication competent adenovirus (RCA) using the 21-day bioassay described below. For the first serial passage, cell factories containing 293 or SL0003 were infected with purified rAd-β-gal (p0) at 5 x
20 10e8 particles/ml. Cell lysates, prepared when the infections were complete were used to infect a second set of fresh 293 or SL0003 cells seeded in cell factories. Lysates for infection of passages 2 to 5 were prepared similarly and at passage 5, virus was purified by column chromatography.

Assay for RCA

25 A modified bioassay based on a previously described protocol (Zhu *et al.*, (1999) Hum. Gene Ther. 10:113-121) was used to detect RCA using 1 x 10e11 total particles of rAd-β-gal purified after propagation in 293 or SL0003. For the

initial RCA bioassay infection, 10-T225 flasks were each seeded with 1×10^7 cells of A549 cells and infected, 24 hours later with 1×10^{10} particles per flask of rAd- β -gal prepared from 293 or SL0003 cells. After three days, a cell lysate was prepared from the infected A549 cells and used to infect a second set of flasks that had been seeded with 3×10^6 A549 cells. For the second infection, the rAd- β -gal and control lysates from the first infections were divided in half and used to infect a set of 5-T225 flasks. At 12 days after the initial infection, lysates from the second round of infections were prepared. Each lysate was divided in half and used to infect 5 flasks seeded with 3×10^6 A549 cells and incubated for 9 more days. Control samples included Ad5 wild-type (6 virus particles per 10 flasks) and 1×10^{11} virus particles of rAd- β -gal spiked with 6 virus particles of Ad5 wild-type. Both the spiked and wild-type adenovirus controls were required to produce CPE during the 21 day infection. If CPE was observed in the rAd- β -gal samples during the bioassay, low molecular weight DNA was isolated from approximately 1×10^7 cells for viral DNA analysis.

II. Results

Production Levels

Virus production potential in selected cell lines was assessed by infection with the replication competent virus Ad5-*d*/309. A549 cells and HeLa cells produced virus at 558,000 and 444,000 particles/cell, respectively. Other lines tested including, DLD-1, U87MG, MDA468 and IGROV-1, all produced less than 120,000 particles/cell. 293 cells produced Ad5-*d*/309 virus at 139,000 particles/cell and rAd- β -gal virus at 127,000 particles/cells. The production capacity for Ad5-*d*/309 in HeLa and A549 cell lines suggested that these human tumor lines were the best candidates for use in development of E1-complementing cell lines.

Complementation of E1A in A549 cells

Expression of wild-type E1A has been reported to reduce the proliferative capacity of A549 cells and leads to apoptosis under serum-depleted conditions

(Hubberstey *et al.*, (2002) Cancer Gene Ther. 9:321-329. To limit the toxicities associated with E1A expression in A549 cells, several E1A mutants were tested for stable expression and complementation of E1 function for rAd vector production. The E1A mutants used, E1Ad/1101, E1Ad/1107 and E1Ad/01/07, carried deletions in regions of E1A proteins that were required for induction of cell cycle progression and apoptosis (Figure 1) but did not compromise the E1A transactivation domain required for stimulation of the other early virus promoters. Specifically, the E1Ad/1101 and E1Ad/1107 mutants were defective for binding to the cellular proteins p300/CBP and pRb, respectively, whereas the E1Ad/01/07 mutant was defective for binding both cellular proteins.

Plasmids expressing either E1Ad/1101, E1Ad/1107, E1Ad/01/07 or wild-type E1A under control of an RSV promoter were used to transfect A549 cells. The plasmids also contained a neomycin resistance gene as a selectable marker. Individual clones from pools of G418 resistant cells were isolated and screened by infection with rAd-GFP. The level of GFP expression was visually examined in 48 clones and then five clones were selected for further characterization. The production capacity of each clone (A549E1Ad/1101-1 to A549E1Ad/1101-5, A549E1Ad/1107-1 to A549E1Ad/1107-5, A549E1Ad/01/07-1 to A549E1Ad/01/07-5, A549E1A*wt*-1 to A549E1A*wt*-5) was determined by quantification of rAd-GFP particles produced per cell as described herein. Results of the production assays (see Table 2) show that the cell clones expressing either E1A*wt*, or E1Ad/1101, had low virus productivity. Cell clones isolated from the E1Ad/1107 generally gave poor production yields, with the exception of cell clone E1Ad/1107-1 which had a yield of over 20,000 particles per cell. In contrast, cell clones isolated from the E1Ad/01/07 transfection pool had the highest production yields as four of the five cell clones assayed yielded particle concentrations between 20,000 and 30,000 per cell.

Table 2: rAd-GFP yield from indicated cell clones (virus particles/cell)

Cell Clone #	Clone and E1A Status			
	E1Ad/1101	E1Ad/1107	E1Ad/01/07	E1A _{wt}
Clone #1	2700	21000	7800	1800
Clone #2	2200	800	25000	400
Clone #3	800	4200	23000	0
Clone #4	3600	1200	32000	800
Clone #5	1200	1200	20000	700

Measurement of E1A protein levels in E1A expressing A549 clones

E1A protein levels in the selected clones (E1Ad/1101-1 to E1Ad/1101-5,
 5 E1Ad/1107-1 to E1Ad/1107-5, E1Ad/01/07-1 to E1Ad/01/07-5, E1A_{wt}-1 to E1A_{wt}-
 5) were determined by Western blot analysis using an E1A-specific monoclonal
 antibody (Harlow *et al.*, (1985) J. Virol. 55:533-546) that recognized an epitope in
 the C-terminal region of E1A. This epitope was unaffected by the *d/1101* and
 10 *d/1107* mutations. Western analysis showed that expression levels of E1A proteins
 varied greatly between the clones. In addition, the amount of wild-type or mutant
 E1A protein expressed did not correlate with the production yields. All cell clones
 expressing wild-type E1A or the E1Ad/1101 mutant were inefficient producers
 regardless of the amount of E1A protein expressed. Among the E1Ad/1107 cell
 clones only E1Ad/1107-1 was an efficient producer despite expressing nearly
 15 undetectable levels of E1A protein. The E1Ad/1107-1 cell clone was not further
 analyzed as it grew poorly, a characteristic undesirable in a production cell line.
 The E1Ad/01/07 cell clones also displayed various levels of protein with the best
 producer cell clone E1Ad/01/07-4 expressing lower levels as compared to
 E1Ad/01/07-5, which had comparatively high levels.

Analysis of viral replication and apoptosis after infection

The E1A_{wt}-2 and E1Ad/01/07-5 cell clones, which expressed similar levels of
 E1A proteins, were selected to further characterize the biological basis for the
 different production yields. Because the E1Ad/01/07-4 cell clone produced viral

particles more efficiently than any other line (see Table 2), it was also selected for further characterization.

The ability of the A549-E1A*wt*-2 and the two A549-E1A Δ 01/07 cell clones (E1A Δ 01/07-4 and E1A Δ 01/07-5) to support replication of an E1-deleted virus rAd- β -gal virus was analyzed by restriction enzyme digest of low molecular weight DNA from infected cells. Restriction analysis indicated that there were differences in the quantity and quality of viral DNA isolated from the various cell lines. The quality of rAd- β -gal DNA from the E1A Δ 01/07 cell clones was comparable to 293 cell isolated viral DNA. Extremely low levels of rAd- β -gal viral DNAs were produced from the E1A*wt*-2 clone, and the DNA that was isolated smeared on the agarose gel with DNA fragmentation suggesting high levels of apoptosis in these cells.

Analysis of viral DNA produced from clone E1A*wt*-2 suggested that apoptosis could be occurring, potentially limiting the amount of virus produced. A FITC-VAD-FMK peptide was used to measure caspase activity by flow cytometry as an indicator of apoptotic cell death after infection. As shown in Table 3 almost half of the E1A*wt*-2 cells were apoptotic 20 hours after infection, whereas apoptosis was not induced in the E1A Δ 01/07-4 and E1A Δ 01/07-5 cell clones. Together these results suggest that viral infection of the E1A*wt*-2 cells induces premature apoptosis, limiting viral DNA replication and subsequent virus particle production.

Table 3: Percentage of apoptotic cells at 20 hours after infection with rAd- β -gal

Experiment	Clone			Control
	E1A <i>wt</i> -2	E1A Δ 01/07-4	E1A Δ 01/07-5	A549
Experiment 1	49%	4%	6%	1%
Experiment 2	49%	6%	7%	2%

Status of the E2F and p53 transcription factors in E1A*wt* and E1A Δ 01/07 cell clones

Induction of apoptosis by E1A has been shown to be linked to binding of pRb and p300/CBP, resulting in activation of the E2F and p53 transcription factors (Querido *et al.*, (1997) J. Virol. 71: 3526-3533). To measure E2F and p53 activity

levels in the selected production cell clones, reporter plasmids were constructed in which a luciferase gene was placed under control of either a consensus p53 promoter or an E2F promoter. p53 and E2F promoter activities were found to be elevated in the E1A*wt*-2 clone (see Table 4). In contrast, p53 and E2F activity levels in the E1A*d*01/07-4 and E1A*d*01/07-5 clones were similar to the control A549 cells.

Table 4: Activation of the p53 and E2F transcription factors in the indicated cell clones (relative fluorescence units x 1e+6)

Reporter Plasmid	Clones			Control
	E1A <i>wt</i> -2	E1A <i>d</i> 01/07-4	E1A <i>d</i> 01/07-5	A549
p53-luciferase	3.7 +/- 0.22	0.81 +/- 0.14	0.53 +/- 0.06	1.29 +/- 0.22
E2F-luciferase	4.7 +/- 0.19	0.53 +/- 0.17	0.32 +/- 0.006	1.36 +/- 0.18

Complementation of E1B in E1A*d*01/07-4

Although the E1A*d*01/07-4 clone was capable of producing replication defective adenovirus in small scale format, it was reasoned that the yield may be further improved by complementation using E1B. To study the production yield of E1A*d*01/07-4 cells after E1B complementation, E1A*d*01/07-4 cells were infected, at two different concentrations (1 x 10⁸ particles/ml and 5 x 10⁸ particles/ml), with a series of E1 adenovirus mutants to express E1B-19K and E1B-55K either individually or together. It was found that infection of E1A*d*01/07-4 cells of a virus that produces a non-functional truncated E1A and wild-type E1B (Ad-NT1010) yielded virus comparable to Ad5-*d*309 (see Table 5). In contrast, a mutant virus that expressed E1A but no E1B (AdE1B⁻) yielded only about 55,000 particles per cell after infection at both concentrations of test virus. These results suggested that complementation of E1B increases production yield. To further define the contribution of the E1B region, viruses expressing either E1B-19K (*d*1520) or E1B-55K (AdE1B-19K⁻) alone were tested for growth on E1A*d*01/07-4 cells. The E1B-

19K expressing virus productivity was considerably lower than Ad5-*d*/309 whereas the E1B-55K expressing virus produced at levels higher than Ad5-*d*/309.

Table 5: Virus yield from E1Ad/01/07-4 cells after infection with various E1⁻ mutant adenovirus (E1A, E1B-19K, E1B-55K status indicated)

		Virus				
		<i>d</i> /309	<i>d</i> /1520	E1B19K ⁻	E1B ⁻	NT1010
Status	E1A	+	+	+	+	-
	E1B-55K	+	-	+	-	+
	E1B-19K	+	+	-	-	+
Virus	Yield (1e+8 p/ml)	155000	86000	231000	55000	177000
Yield	Yield (5e+8 p/ml)	242000	84000	306000	58000	261000

5

These results suggested that addition of an E1B-55K gene increases the viral yield in the E1Ad/01/07-4 cell line. Use of only the E1B-55K coding sequences may further reduce the possibility of generating RCA during rAd production. A selection plasmid was used in which the E1B-55K gene was cloned under control of the CMV promoter (pcDNA-55K) to complement E1B-55K function in E1Ad/01/07-4 cells. The sequence of the expression cassette in pcDNA-55K was verified by DNA sequencing and expression of intact E1B-55K protein was demonstrated by transient transfection in HeLa cells.

10

15

20

A549E1Ad/01/07-4 cells were transfected with pcDNA-55K, which also carried a hygromycin resistance marker, and individual clones (A549E1Ad/01/07-4-E1B-55K-1 to A549E1Ad/01/07-4-E1B-55K-6) were selected from the drug-resistant pool by dilution cloning. Clones were screened for E1B-55K function using an immunofluorescent assay that measured inhibition of a p53 responsive promoter (PRE) controlling GFP expression carried in a replication defective adenovirus named rAd-PRE-GFP. In cells expressing wild type p53, such as the parental A549E1Ad/01/07-4 line, GFP was expressed at high levels from rAd-PRE-GFP. In contrast, expression of GFP from rAd-PRE-GFP was low in 293 cells (control) and A549E1Ad/01/07-4-E1B-55K cells, which express E1B-55K and wild-type p53.

Several clones including A549E1Ad/01/07-4-E1B-55K-2 were selected using this assay and further characterized for E1B-55K expression and virus production.

Similar levels of E1B-55K protein were detected by immunoprecipitation, with the E1B-55K specific monoclonal antibody 2A6, in cell lysates from all of the selected clones (A549E1Ad/01/07-4-E1B-55K-1 to A549E1Ad/01/07-4-E1B-55K-6) and one clone A549E1Ad/01/07-4-E1B-55K-2, hereafter designated SL0003, was selected for further characterization based on its growth properties and virus production.

Cell line stability is important for pharmaceutical scale-up production and therefore the virus growth capacity of SL0003 cells was evaluated during 20 cell culture passages. Table 6 shows that SL0003 cells assayed at passage 5, 15 and 20 produced rAd- β -gal virus at an average of about 96,000 particles per cell.

Table 6: rAd- β -gal yield from SL0003 cells

SL0003 Passage No.	Particle No. (+/- Std.Dev.)
5	88800 +/- 2800
15	105600 +/- 3700
20	93021 +/- 2800

RCA testing of virus produced in SL0003 cells

To test for RCA generation during production of rAd vectors, rAd- β -gal was serially-passaged in either SL0003 cells or 293 cells grown in cell factories containing approximately 1×10^9 cells, using a RCA-free virus lot as the initial inoculum. The bioassay used for detection of RCA had a sensitivity level of 1 particle of wild-type virus per 1.7×10^{10} particles of rAd- β -gal (see above). After five serial passages, RCA was detected in rAd- β -gal virus purified from 293 cells, but no RCA was detected in rAd- β -gal purified from SL0003 cells. PCR analysis confirmed that the virus detected in the RCA assay from the 293 cells arose from recombination rather than contamination by Ad5.

III. Discussion

As exemplified herein, a human cell line (designated "SL0003") was created which incorporates separate expression cassettes, the first expression cassette containing an adenoviral E1A gene comprising the Δ 01/07 deletions and a second expression cassette containing the adenoviral E1B-55K gene which provides selected viral and cellular functions to complement adenovirus replication in A549 tumor cells. Optimization of E1 complementation in SL0003 cell line was achieved using sequential addition of separate E1A and E1B expression cassettes. In the SL0003 cell line, the E1A Δ 01/07 mutant gene was constitutively expressed to provide E1A function and to reduce cellular toxicity associated with wild-type E1A. E1B function in the SL0003 cell line was provided by constitutive expression of the E1B-55K gene; the E1B-19K gene was not included. Separation of the E1A and E1B cassettes, use of a mutant E1A gene, and only the E1B-55K gene eliminated the possibility of reconstitution of an intact E1 region through either homologous or non-homologous recombination and subsequent generation of RCA. Although the adenovirus sequences used for complementation in the SL0003 cell line are extensively modified compared to the wild-type E1 adenovirus sequence in 293 cells, the SL0003 cell line was shown to produce rAd vectors at viral production levels comparable to those obtained from the 293 cell line and without generation of detectable RCA.

Example 2: Generation an E1A, E1b and E2b Complementing
Cell Line and Use of the Cell Line in
the Production of Recombinant Adenovirus

This example demonstrates the utility of an E1A, E1b and E2b
complementing cell line for the production of high titers of replication-defective,
helper-independent recombinant viruses.

I. Materials & Methods

Tissue Culture

A549, CHO-K1, Saos2, HeLa, and HepG2 cells were all purchased from
ATCC. C7 cells (Amalfitano et al. (1996) PNAS 93:3352-3356) were kindly provided
by J. Chamberlain, U. of Michigan. Human Tenon's capsule ocular fibroblast cells
(designated as HOF cells) were isolated as described in Perkins et al ((2002) Arch.
Ophthalmol. 120 :941-9). The development of Clone 4 cells are described above in
Example 1; the clone is designated clone E1A01/07-4i. A549, C7, and HepG2 cells
were maintained in Dulbecco's modified Eagle's medium (DME) supplemented with
10% fetal bovine serum (FBS). HeLa cells were maintained in Eagle's minimal
essential media (MEM) supplemented with 5% FBS. CHO-K1 and Saos2 cells were
maintained in Hams F12/DME media supplemented with 10% FBS. HOF cells were
maintained in DME + 20% FBS. Clone 4 cells were maintained in DME + 10% FBS
supplemented with 350 ug/ml of G418 (Geneticin, Invitrogen).

Isolation of Ad E2b Pol Expressing Cells

Clone 4 cells were transfected with 10 µg of linearized plasmid
pMGCMVE2bPol using CaPO4 transfection (Sambrook et al. Molecular Cloning: A
Laboratory Manual (1998) Cold Spring Harbor Laboratory Press, Plainview, New
York). Following transfection, the cells were selected in DME + 10% serum
supplemented with 150 µg/ml of hygromycin. The pool underwent limiting dilution
cloning under drug selection and clone 3D8 was chosen. Clone 3D8 was grown in
DME + 10% serum supplemented with 150 µg/ml of hygromycin and 350 ug/ml
G418.

Isolation of Ad E1b Expressing Cells

15M15 cells were derived from clone 3D8 described above. 3D8 cells were transfected with 10 µg linearized pVITRO2IRESpuromycinE1b (Figure 4) using CaPO₄ transfection as before. Clone 15 was originally isolated from transfected pools treated with 0.2 µg/ml puromycin. Clone 15M15 was further isolated from clone 15 through limiting dilution isolation and propagated in DME + 10% FBS supplemented with 350 µg/ml of G418, 150 µg/ml of hygromycin, and 0.2 µg/ml of puromycin.

Plasmid Constructs Expressing Adenovirus Functions

Adenovirus E2b polymerase sequence was isolated from the plasmid pACN (Wills et al. (1995) Can. Gene Ther. 2:191-197) by PCR utilizing primers to add the first three upstream amino acids 'MAL', as described by Shu et al. (1988) Virol. 165:348-356, to the rest of the Ad 5 E2b polymerase coding sequence. The primers also added restriction sites allowing the PCR fragment to be cloned into the vector pMG (InvivoGen, San Diego, CA) downstream of the CMV promoter into the Bam HI restriction site. The resulting plasmid was named pMGCMVE2Bpol (Figure 5). The CMV driven full-length E2b polymerase coding sequence was followed by an IRES sequence and the hygromycin resistance gene which was used for selection.

The plasmid pIRESpuromycin2 (from Clontech, Palo Alto, CA) was digested with NdeI and BstBI, and the 4.7 kb fragment containing the ampicillin and puromycin resistance genes were isolated from a 1% TAE agarose gel following the protocol from the QIAEX II gel extraction kit from Qiagen (Valencia, CA). The plasmid pVITRO2 (from InvivoGen, San Diego, CA) was digested with NdeI and AccI, and the 3.9 kb fragment containing the human ferritin light and heavy subunit promoters with enhancers was isolated from a 1% TAE agarose gel as above. The two fragments were ligated together to form the plasmid pVITRO2IRESpuromycin. Adenovirus E1b sequence was isolated from the adenoviral plasmid pTG4609 (Transgene, FR) by PCR and subcloned into the plasmid pCR-Blunt II TOPO (Invitrogen, Carlsbad, CA) cloning vector. From there, the E1b fragment was

digested out with EcoRI and BamHI and treated with Klenow and blunt end cloned into EcoRV digested pVITRO2IRES^{Puro}. This created the plasmid pVITRO2IRES^{Puro}E1b which had the E1b region driven by the human ferritin heavy subunit promoter and SV40 enhancer with a puromycin resistance gene for cell selection. The correct orientation of the E1b sequence was verified through restriction digestion patterns.

Viral Constructs

The construction of GFCB has been described previously (Cheney *et al.*, (1998) Can. Res. 58: 2331-2334). Briefly, it is an E1,pIX, E3 deleted virus expressing the enhanced green fluorescent protein (eGFP, Clontech, Palo Alto, CA) from the human cytomegalovirus immediate-early promoter/enhancer and Ad 2 TPL cDNA from the E1 deleted region, utilizing the E1b/pIX viral polyA signal to terminate its message. CONG has also been described previously. It contains a consensus p53 response element driving eGFP in the 3' to 5' orientation in the deleted E3 region of an E1/E3 deleted viral backbone similar to GFCB. The viral constructs CGAB, 42GC, 46GC, and 2GCP all utilize the same expression cassette isolated from the plasmid pEGFP-N1 (Clontech, Palo Alto, CA). The cassette contains the human CMV immediate-early promoter / enhancer, the enhanced green fluorescent protein gene, and the SV40 early mRNA polyadenylation signal. For CGAB, this expression cassette replaces that contained in GFCB. 42GC, 46GC and 2GCP all contain their expression cassettes in the 5' to 3' orientation in the E3 deleted region of the viral backbone. 42GC and 2GCP are also E1a and E1b deleted, with pIX remaining intact. 46GC is an E1 intact virus and is replication competent. The 2GCP virus also has approximate 600 bp deletion in the E2b viral DNA polymerase region as reported in Amalfitano et al. (1998) ((1996) PNAS 93: 3352-3356) rendering it replication incompetent in the absence of exogenous E2b polymerase protein.

Western

To determine E2b polymerase expression levels, clones 3C4, 3C9, 3D8, and parental clone 4 and A549 cells were seeded in 10 cm dishes. The cells were incubated and allowed to grow for 2 days and then harvested. Equal protein, as
5 determined by Bradford assay (Bio-Rad cat# 500-0006), was loaded onto a 4-12% NuPAGETM Bis-Tris gel (Invitrogen, Carlsbad, CA). The protein was transferred and the filter was blocked, then incubated with a 1:2,000 dilution of rabbit anti E2b polymerase polyclonal antibody (provided by Dr Padmanabhan, U. Kansas), followed by a 1:2,000 dilution of goat anti-rabbit IgG-HRP (Jackson
10 ImmunoResearch, West Grove, PA). The filters were developed with SuperSignal West Pico Chemiluminescent kit (Pierce, Rockford, IL) and exposed to film. The filters were then stripped and re-probed with β -actin (Sigma, St. Louis, MO) at a 1:10,000 dilution, followed by sheep anti- mouse IgG-HRP (Amersham Biosciences, Piscataway, NJ) at a 1:2,000 dilution.

15 In determining adenovirus late gene protein expression, CHO, HELA, HepG2, and 15M15 cells were seeded in 6 well plates and infected the following day with 5×10^8 P/ml of CGAB, 42GC, 2GCP, 46GC or GFCB virus. The cells were harvested 4 days post transduction, and total protein content was determined by Bradford assay. Equal total protein was loaded onto 4-12% NuPAGE Bis-Tris gel and
20 transferred onto PVDF filters (Millipore Corp, Bedford, MA). The filters were incubated with rabbit anti sera to Adenovirus type 5 (Access Biomedical, San Diego, CA) at a 1:2,500 dilution, followed by a 1:2,000 dilution of goat anti-rabbit IgG-HRP. The filters were then processed as described above.

Virus Productivity

25 To evaluate the viral productivity in the engineered cells, selected clones were seeded in 10 cm dishes and infected with 5×10^8 p/ml of 2GCP virus. An additional control plate was seeded for counting at the time of infection. Infected cells were harvested 3 – 4 days post infection when the majority of cells had
30 rounded up and lifted off the plate, indicating viral replication had occurred. Virus was released from the cellular lysates by 3 cycles of freeze / thawing and removal

of cellular debris by centrifugation. Virus was then purified and quantitated by column chromatography as described previously (Shabram *et al.* (1997) Hum. Gene Ther. 8: 453-465).

Productivity was determined by dividing the total virus particles by the number of cells at the time of infection, giving the virus particle per cell ratio as a measure of productivity of the cells in complementing virus growth.

Cytofluor / Transgene expression

Cells were seeded in 6 well plates and returned to their incubators until they had reached 80-90% confluency. They were then infected with 5×10^8 P/ml of viruses in triplicate in a total volume of 3 ml per well. Cells were measured for GFP transgene expression using the CytoFluor Series 4000 Multi-well plate reader (PerSeptive Biosystems) and photographed using a Hammamatsu 3CCD analog camera and controller. GFP fluorescence is plotted as the average of relative Cytofluor values for the triplicate wells at each time point, minus background fluorescence, and +/- the standard deviation. Twice a week, 0.5 ml of fresh media was added per well for all cells.

E1b Complementation

Clones to be analyzed for E1b expression were seeded in 6 well plates and allowed to incubate and grow until they had reached approximately 80-90% confluency. At this point, the cells were infected with 5×10^8 P/ml of either GFCB or CONG virus in triplicate. Infected cells were then photographed using a Hammamatsu 3CCD analog camera and controller and assayed for GFP fluorescence using the CytoFluor Series 4000 Multi-well plate reader (PerSeptive Biosystems) set at 450 nm excitation and 508 nm emission at 48 hours post-infection. Average values from the duplicate wells +/- standard deviation were plotted as the ratio of CONG fluorescence over the GFCB derived fluorescent values.

II. Results

Addition of E2b polymerase to E1a complementing cells

Following transfection of clone 4 cells with the E2b polymerase expressing plasmid pMGCMVE2bPol, resistant cells were selected by treatment with hygromycin and isolated as individual clones by limiting dilution purification.

5 Western analysis of cellular lysates was used to select clones specifically expressing the 140 kd band representing E2b polymerase. In Figure 7A, the clones 3C4, 3C9, and 3D8 all show the expected band for E2b Pol. This band is not present in the parental clone # 4, or in A549 cells upon which all clones were based. All lanes were loaded at equal total protein concentrations as determined by Bradford assay
10 and verified by β -actin detection. Since equal total protein was loaded per lane, the density of the polymerase band should reflect its level of expression in that particular clone. When compared to the ability of the particular clones to produce the polymerase deleted virus 2GCP, there is a positive correlation between the amount of polymerase expressed and the productivity of the clone (Figure 7B).
15 Since clone 4 was not engineered to express E2b polymerase, it is not able to support the growth of a polymerase deleted virus and no virus was recovered. Clone 3D8 expressed the highest amount of polymerase protein and also produced the most virus particles per cell. This clone was chosen for further analysis and was used as the parental line for introducing and expressing adenovirus E1b
20 proteins.

Addition of E1b to 3D8

Clone 3D8 was transfected with the E1b encoding plasmid pVITRO2IRESpuromycinE1b, and individual clones resistant to puromycin treatment were
25 selected and isolated as before. A functional assay was used to detect E1b function during the isolation process using the viruses CONG and GFCB. Clones isolated by limiting dilution which had been expanded to duplicate 6 well plates and were infected with 5×10^8 P/ml of CONG or GFCB virus. Forty eight hours later, GFP expression from the infected clones was measured by Cytofluor analysis.
30 Infection with GFCB is used to control for potentially differing infectability of clones to adenovirus and so that a ratio of E1b mediated decrease in GFP fluorescence

can be established. CONG is a virus using a p53 consensus sequence response element (p53RE) to drive GFP expression. The clones are based on A549 cells, which are positive for p53 expression. Therefore, infection of A549 based clones such as 3D8 will lead to p53 mediated expression of GFP. Adenovirus E1b 55 kd protein is known to bind p53 and convert it from a transcriptional activator to a transcriptional repressor (Yew and Berk (1992) Nature 357:82-85, Roth and Dobbelstein (2003) Methods Mol. Biol. 234:135-149). Clones expressing E1b 55 should then bind up p53 and prevent or reduce GFP fluorescence from CONG infected cells. Although the p53RE driving GFP expression is a weaker promoter than the CMV utilized in GFCB, clones expressing E1b proteins should lead to a further decrease in GFP expression from CONG dependent on the amount of E1b 55 expressed. In Figure 8A, parental cell line 3D8 and three clones infected with either GFCB or CONG virus were photographed and their GFP fluorescence levels were quantitated using Cytofluor analysis. In Figure 8B, the ratio of GFP fluorescence from CONG to GFCB was plotted. The change in values represents the varying degrees of decrease in GFP expression from CONG infections relative to the parental 3D8 clone due to differences in expression of E1b 55kd from the cells. Clone 15 showed the greatest differential, suggesting that it should be expressing the greatest amount of E1b protein. It was shown above that the addition of E1b 55 to A549 based clones already expressing E1a function leads to an increased productivity of virus growth in the cells. When the clones in Figure 8 were tested for productivity in the growth of 2GCP virus, an inverse correlation was found between the degree of GFP expression and productivity (Figure 8C). Clones which showed the greatest decrease in GFP expression, which should result from greater expression of the E1b 55 protein, had the greatest increase in productivity compared to the non-E1b expressing parental clone 3D8 (Figure 8C). Based on these results, clone C15 was chosen for further study.

Final Clone analysis 15M15

Clone 15 underwent further purification through sub-cloning in a combination selection media of G418, hygromycin, and puromycin. This

combination should select for retention of E1a, E1b and E2b function. Further screening of isolated clones by productivity assays with 2GCP virus led to the selection of 15M15 as the final choice for the new complementing cell line. In Figure 9A shows the productivity of clone 15M15 for 2GCP growth compared to its parental clone 3D8, as well as to C7 cells. C7 cells are based on the Ad E1 complementing 293 cells which have been further engineered to also express E2b polymerase (Amalfitano et al. (1996) PNAS 93:3352-3356). The 15M15 cell line is able to propagate the polymerase deleted virus 2GCP to a higher extent than its 293 based counterpart (C7) or its E1b lacking parental cell line 3D8. The genomic stability of the new line was tested by serial passage and infection of the cells either in their complete selection media mix or just media alone. Figure 9B shows the results of viral productivity under each condition at passages 1, 5, and 10 for cells infected with 2 different doses of 2GCP virus. The clone's ability to complement the adenovirus functions necessary to propagate polymerase deleted virus to high yields appears very stable through 10 passages, even without selection drugs in the media. Western analysis was used to detect the E1a and E2b polymerase proteins from cells isolated at passages 1, 5, and 10. As shown in Figure 9C, both proteins also appeared to be stable over 10 passages, even in the absence of selection media.

Viral Constructs

Figure 6 shows a schematic for the viruses used in this study. The E3 and E1 deletions indicated are the same for all but two of the viruses. For control virus GFCB, the E1 deletion extends an additional 700 base pairs into the pIX coding sequence, allowing the E1b/pIX viral polyA signal to be used for the GFP expression cassette. Virus 46GC is E1 wild-type and replication competent. The CMV-GFP-pA expression cassette is identical for the CGAB, 42GC, 2GCP and 46GC viruses as verified by restriction analysis, PCR, and sequencing. In the CONG virus, the CMV promoter in the expression cassette is replaced by a p53 consensus response element to drive the GFP gene. The E2b polymerase deletion in 2GCP restricts its

growth to cell lines expressing E2b polymerase. 2GCP was originally isolated in the E2b polymerase expressing cell line C7.

Decreased Late Ad Gene Expression

5 Infected cell lysates were analyzed for adenovirus protein expression by Western analysis using polyclonal antibody against Ad 5. The complementing producer cell line 15M15 was infected with GFCB, CGAB, 42GC, and 2GCP. All 4 viruses are able to replicate well in this cell line and all show expected viral bands (Figure 10A).

10 CHO cells were infected with CGAB, 42GC, 2GCP and 46GC virus. As shown in Figure 10B, only the replication competent 46GC virus showed any viral bands corresponding to hexon and fiber in this non-complementing cell line.

 HeLa and HepG2 cells were infected with CGAB, 42GC, 2GCP and 46GC virus. HepG2 cells were also infected with GFCB virus. HeLa cells are able to partially complement E1a function due to the expression of the E7 gene from integrated human papillomavirus (Schneider-Gadicke and Schwarz (1986) EMBO 5:2285-2292, Phelps et al. (1988) Cell 53:539-547), while HepG2 cells have been reported to have high NFIL-6 responsive activity, which can functionally substitute for E1a in activation of other adenovirus promoters (Spergel and Chen-Kiang (1991) PNAS 88:6472-6476). In both cell lines, there is a greatly reduced or absent expression of viral proteins observed with the polymerase deleted 2GCP virus compared to the other E1/ E3 deleted but polymerase intact viruses (Figures 10C and 10D). These results are in agreement with the findings of others using viruses deleted for essential replication functions (refs, E2b pol, pTp, DBP). A decrease in the ability of a virus to express its own proteins in infected cells is the basis for reducing the immune mediated clearance of infected cells and prolonging transgene expression (Yang *et al.*, (1994) PNAS 91: 4407-4411; Gilgenkrantz *et al.*, (1995) Hum. Gene Ther. 6: 1265-1274; Yang *et al.*, (1995) J. Immunol. 155: 2564-2570). The replication competent 46GC virus shows the highest levels of viral proteins as expected.

Improved Transgene Expression

In comparing GFP fluorescence *in vitro*, despite having identical expression cassettes, there was a consistent ranking of constructs. GFP fluorescence was consistently greatest with 2GCP, followed by 42GC, and then CGAB. This was found in multiple cell types, including CHO, Saos 2, and human ocular fibroblasts (HOF) cells as shown in Figure 11. Cytofluor values are plotted as the average from triplicate infections +/- their standard deviation, along with representative pictures of the cells infected with the indicated constructs for HOF and Saos 2 cells in Figure 11A-D and for CHO cells in Figure 11E-F. The high levels of *in vitro* expression from the new constructs persisted over extended periods of time.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

What is claimed is:

1. A recombinant adenovirus production cell line, designated SL0003, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6231.
2. A recombinant adenovirus production cell line, designated SL0006, deposited with the American Type Culture Collection (ATCC) under accession number PTA-6663.
3. A method for producing recombinant adenovirus comprising culturing the human cell line designated SL0003 transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the human cell line is deposited with the American Type Culture Collection under accession number PTA-6231.
4. A method for producing recombinant adenovirus comprising culturing the human cell line designated SL0006 transfected with recombinant adenovirus vector under conditions so as to permit replication of the viral genome in the cell line, wherein the human cell line is deposited with the American Type Culture Collection under accession number PTA-6663.
5. The method of claim 3 or 4, wherein the recombinant adenovirus is replication-defective.
6. The method of claim 3 or 4, wherein the recombinant adenovirus comprises a heterologous gene.




FIG.1

2/20




FIG.2

3/20




FIG.3

4/20




FIG.4

5/20




FIG.5

6/20





FIG.6

7/20

FIG. 7A



8/20

PRODUCTIVITY OF 2GCP IN E1α+E2b POL CLONES







FIG.7B

9/20

FIG. 8A



10/20

**FIG.8B****FIG.8C**




FIG.9A

CLONE 15M15

STABILITY OF VIRAL PRODUCTIVITY







FIG.9B





14/20

FIG. 10



15/20

HOF CELLS






FIG.11A




16/20

HOF Cells



CGAB



2GCP

FIG.11B

17/20

SAOS 2 CELLS





FIG.11C



18/20






FIG. 11D

19/20


CHO Cells Day 15



CGAB



42GC



2GCP

FIG. 11E

20/20




FIG.11F

